Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),TNNI3 Precentage (TTNI1) Quantiles - Q1 (>16.15 and ≤26) (4),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Cell Line Sex - Both (118),Cell Line Sex - Male (64),Cell Line Sex - Female (40),Cell Line Ancestry - Caucasian (41),Cell Line Ancestry - Asian (28),Disease Modelling - Genetic Disorders (18),Disease Modelling - Arrhythmic (15),Disease Modelling - Ischemic Infarction (9),Disease Modelling - Dilated Cardiomyopathy (6),Disease Modelling - Hypertrophic Cardiomyopathy (6),Disease Modelling - Fibrotic (4),Pharmacological Intervention - Adrenaline (83),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Pharmacological Intervention - Isoproterenol (71),Pharmacological Intervention - QT-Prolonging Drugs (36),Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Pharmacological Intervention - Verapamil (27),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Pharmacological Intervention - E4031 (22),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Pharmacological Intervention - Traditional Chemotherapy Agents (18),Pharmacological Intervention - Doxorubicin (17),Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Pharmacological Intervention - Other Antiarrhythmic Agents (13),Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Pharmacological Intervention - Epinephrine (11),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Pharmacological Intervention - Positive Inotropes (9),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Pharmacological Intervention - Cisapride (8),Pharmacological Intervention - Ranolazine (7),Pharmacological Intervention - Lidocaine (7),Pharmacological Intervention - Carbamylcholine (6),Pharmacological Intervention - Propranolol (5),Pharmacological Intervention - Blebbistatin (5),Pharmacological Intervention - Metoprolol (5),Pharmacological Intervention - Caffeine (4),Pharmacological Intervention - Carbenoxolone (4)
Metabolic Component Category - Signaling Pathway Regulators (6),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),3D Tissue Media - Iscove (5),Contractile Analysis Method - Force Transducer (27),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - Cell Stem Cell (6),Seeding Confluency (%) - 80 to 84 (12),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Disease Modelling - Arrhythmic (15),Publication Year - 2021 (43),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),3D Stromal Cell Source - hiPSC-MuralC (3),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),TNNI3 Precentage (TTNI1) Quantiles - Q1 (>16.15 and ≤26) (4),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Cell Coculture - Endothelial Cell (35),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Platform - Collagen (38),Deduced Culture Strategy - 3D Only (157),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Contractile Analysis Method - Traction Force Microscopy (9),Contractile Analysis Method - Traction Force Microscopy (9),hiPSC-CM Purification Duration (days) - 4 days (29),Contractile Analysis Method - Motion Tracking (93),Journal - Stem Cell Reports (23),2D Surface - Electrospun (13),Publication Year - 2021 (43),Maturation Strategy - ECM (21),hiPSC-CM Purification Duration (days) - 5 days (6),Electrophysiology Analysis Method - Optical Mapping (39),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),TNNI3 Precentage (TTNI1) Quantiles - Q1 (>16.15 and ≤26) (4),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Cell Coculture - Cardiomyocyte (157),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Platform - Scaffold Free (43),3D Platform - Scaffold Free (43),Publication Year - Post 2020 (122),Sacromere or Cellular Alignment Analysis - Yes (72),Sacromere or Cellular Alignment Analysis - Yes (72),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Contractile Analysis Method - Force Transducer (27),Contractile Analysis Method - Deflection (39),Maturation Strategy - Tension (64),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),Contractile Analysis Method - Motion Tracking (93),Journal - Biomater Sci (7),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Seeding Confluency 2D (%) - 80 to 84 (5),Metabolic Component - Dexamethasone (7),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Publication Year - 2016 (32),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Sacromere or Cellular Alignment Analysis - Yes (72),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Journal - ACS Appl Mater Interfaces (4),Purification Protocol - Cell Sorting (7),Differentiation Purity Assessment - IHC a-actinin (8),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Journal - Int J Mol Sci (3),Number of Cell Lines - 4 (11),Cell Line Ancestry - Caucasian (41),Cell Line - WTC11 (30),Cell Line - IMR90 (19),Cell Line Sex - Both (118),Cell Line - WTC11 (30),Coating for Replating - Laminin (5),Coating for Replating - Laminin (5),Seeding Confluency 3D (%) - 90 to 94 (13),2D Surface - Micropatterned (27),hiPSC-CM Purification Duration (days) - <3 days (31),3D Tissue Media - Commercial Kit (21),Calcium Handling Analysis Method - Visual (104),Calcium Handling Analysis Method - Visual (104),Calcium Handling Analysis Method - Visual (104),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Wnt Inhibitor - KY02111 (7),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Journal - Sci Rep (24),Journal - Sci Rep (24),Electrophysiology Analysis Method - Microelectrode (31),Number of Cell Lines - 3 (29),hiPSC-CM Maturation Media - iCell Maintenance (83),Cell Line - iCell2 (8),Number of Cell Lines - 3 (29),Cell Line - Cor.4U (16),Journal - Toxicological Sciences (4),Journal - Nat Commun (13),Cell Line - iCell (47),Cell Line - iCell (47),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Cell Line - Cor.4U (16),Seeding Confluency (%) - 85 to 89 (43),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Journal - Tissue Eng Part C Methods (6),Cell Line - iCell (47),Metabolic Component - Dexamethasone (7),Publication Year - 2015 (19)
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Number of Cell Lines - 2 (50),Cell Line - BJ1 (7),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Cell Line Ancestry - Asian (28),Calcium Handling Analysis Method - Visual (104),hiPSC Matrix Coating - Rare (8),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),hiPSC-CM Media Supplement - GlutaMax (8),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Cell Line - 201B6 (3),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Journal - Stem Cell Reports (23),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Cell Coculture - Stromal Cell (78),Deduced Culture Strategy - 3D Only (157),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Sacromere or Cellular Alignment Analysis - Yes (72),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),New Media for Maturation - RPMI-1640 (30),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),hiPSC Matrix Coating - Geltrex (33),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Calcium Handling Analysis Method - Visual (104),3D Stromal Cell Source - Stromal Cell (35),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Journal - J Biomed Mater Res A (3),Electron Imaging - Transmission (62),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),3D Platform - Collagen (38),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Deduced Culture Strategy - 3D Only (157),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Deduced Culture Strategy - 3D Only (157),Publication Year - 2020 (51),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Wnt Inhibitor - XAV939 (24),Sacromere or Cellular Alignment Analysis - Yes (72),Cell Line Sex - Both (118),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Contractile Analysis Method - Deflection (39),Maturation Strategy - Tension (64),3D Platform - Collagen (38),3D Platform - Gelatin (6),Sacromere or Cellular Alignment Analysis - Yes (72),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Seeding Confluency (%) - 80 to 84 (12),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Pharmacological Intervention - Isoproterenol (71),3D Platform - Scaffold Free (43),Cell Coculture - Stromal Cell (78),Seeding Confluency 2D (%) - 90 to 94 (12),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Cell Line - Rare (132),2D Surface - Microelectrode Array (9),Disease Modelling - Arrhythmic (15),Electrophysiology Analysis Method - Patch Clamp (59),Journal - Int J Mol Sci (3),hiPSC-CM Maturation Media - RPMI-1640 (153),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Cell Line - WTC11 (30),Cell Line Ancestry - Asian (28),Cell Line Ancestry - Caucasian (41),Cell Line - PGP1 (11),Cell Line Sex - Male (64),2D Surface - ECM-coated (115),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Metabolic Component Category - Sugars and Carbohydrates (9),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Insulin Start Day - 7 (85),3D Stromal Cell Source - Cardiac Fibroblast (32),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),2D Surface - Microelectrode Array (9),Journal - Toxicological Sciences (4),Journal - Toxicological Sciences (4),Journal - Toxicological Sciences (4),Journal - Toxicological Sciences (4),Maturation Strategy - Electrical (39),Journal - Biomaterials (16),Cell Line - iCell (47),Coating for Replating - Matrigel (65),Cell Line - iCell (47),Journal - Toxicological Sciences (4),Journal - Nat Commun (13),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Cell Line - Cor.4U (16),Cell Line - iCell (47),Cell Line - iCell (47),Journal - Toxicological Sciences (4),Journal - Toxicological Sciences (4),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Cell Line - Cor.4U (16),Journal - Int J Mol Sci (3),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Journal - Biomaterials (16),3D Tissue Media - Growth Factor (12),Journal - Sci Rep (24),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Cell Line - iCell (47)
Electrophysiology Analysis Method - Patch Clamp (59),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Maturation Strategy - Tension (64),Cell Line - BJ1 (7),Cell Coculture - Stromal Cell (78),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Pharmacological Intervention - Isoproterenol (71),Seeding Confluency 2D (%) - 80 to 84 (5),Calcium Handling Analysis Method - Visual (104),Disease Modelling - Genetic Disorders (18),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Wnt Induction - Wnt3a (3),Journal - Stem Cell Reports (23),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Journal - Stem Cell Reports (23),Cell Coculture - Cardiomyocyte (157),3D Endothelial Cell Source - hiPSC-EndothelialC (16),3D Stromal Cell Source - Stromal Cell (35),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Cell Coculture - Cardiomyocyte (157),Electron Imaging - Transmission (62),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Journal - Stem Cell Res Ther (3),Cell Line - Gibco episomal (10),Journal - ACS Appl Mater Interfaces (4),Calcium Handling Analysis Method - Visual (104),Publication Year - 2022 (20),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Journal - Am J Physiol Heart Circ Physiol (4),Maturation Strategy - Mechanical (36),Gene Analysis Method - RNA (169),Number of Cell Lines - 2 (50),hiPSC Backbone Media - StemPro-34 (14),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Cell Coculture - Stromal Cell (78),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Deduced Culture Strategy - 3D Only (157),Deduced Culture Strategy - 3D Only (157),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Contractile Analysis Method - Traction Force Microscopy (9),Insulin Start Day - 7 (85),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Journal - Am J Physiol Heart Circ Physiol (4),hiPSC-CM Media Supplement - FBS (16),Publication Year - 2021 (43),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Stromal Cell Source - hiPSC-MuralC (3),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Electrophysiology Analysis Method - Patch Clamp (59),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Journal - Biomater Sci (7),Seeding Confluency 2D (%) - 70 to 79 (6),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Seeding Confluency 2D (%) - 70 to 79 (6),Calcium Handling Analysis Method - Visual (104),Insulin Start Day - 0 (7),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Insulin Start Day - 9 (10),Journal - Cell Stem Cell (6),Insulin Start Day - 2 (4),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Journal - Cell Stem Cell (6),Cell Line Ancestry - Asian (28),Cell Line - DF19-9-11T.H (16),Cell Line - 201B7 (9),Cell Line Sex - Female (40),Cell Line Sex - Both (118),hiPSC Matrix Coating - Geltrex (33),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Publication Year - 2024 (7),3D Tissue Media - Iscove (5),Cell Line Ancestry - Caucasian (41),3D Stromal Cell Source - Human Fibroblast (38),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Contractile Analysis Method - Motion Tracking (93),Contractile Analysis Method - Motion Tracking (93),Cell Line - iCell (47),Cell Line - iCell (47),Calcium Handling Analysis Method - Visual (104),hiPSC-CM Maturation Media - iCell Maintenance (83),Wnt Inhibitor - Others (9),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Calcium Handling Analysis Method - Visual (104),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),Wnt Inhibitor Duration (days) - >6 days (12),Cell Line - iCell2 (8),hiPSC-CM Maturation Media - iCell Maintenance (83),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),Journal - Cell Rep (6),Number of Cell Lines - 4 (11),3D Platform - Fibrin (50),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Coating for Replating - Gelatin (43),Cell Line - iCell (47),Journal - Toxicological Sciences (4),3D Tissue Media - Iscove (5),Cell Line - IMR90 (19),Journal - ACS Appl Mater Interfaces (4),Electrophysiology Analysis Method - Microelectrode (31),Metabolic Component - T3 (14),hiPSC-CM Media Supplement - iCell Maintenance Medium (41)
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Coating for Replating - Rare (6),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Pharmacological Intervention - Adrenaline (83),Cell Line - WTC11 (30),Journal - Cell Stem Cell (6),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Publication Year - 2015 (19),hiPSC Matrix Coating - MEF feeder cells (8),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Maturation Strategy - Tension (64),Disease Modelling - Genetic Disorders (18),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Deduced Culture Strategy - 3D Only (157),Cell Coculture - Stromal Cell (78),Maturation Strategy - Other Cells (80),Cell Coculture - Cardiomyocyte (157),3D Endothelial Cell Source - hiPSC-EndothelialC (16),Wnt Induction Duration (days) Quantiles - Q2 (>1 and ≤2) (75),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Maturation Strategy - Cell Alignment (59),Journal - PLoS One (9),Wnt Inhibitor - IWR (56),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Pharmacological Intervention - Phenylephrine (3),Journal - Biomater Sci (7),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Insulin Start Day - 5 (14),2D Surface - Micropatterned (27),Cell Line - ATCC (5),hiPSC Backbone Media - Conditioned (12),Cell Line - Cor.4U (16),Pharmacological Intervention - T3 (3),TNNI3 Precentage (TTNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Disease Modelling - Genetic Disorders (18),Cell Coculture - Endothelial Cell (35),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Cell Coculture - Cardiomyocyte (157),3D Tissue Media - Commercial Kit (21),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Cell Line - Gibco episomal (10),Cell Line - IMR90 (19),hiPSC Backbone Media - mTeSR (106),Journal - J Tissue Eng (4),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),3D Platform - Fibrin (50),3D Platform - Matrigel (33),3D Tissue Media - RPMI-1640 (72),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Seeding Confluency 3D (%) - 80 to 84 (5),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),3D Stromal Cell Source - Stromal Cell (35),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Stromal Cell Source - Stromal Cell (35),Day of Insulin Addition - not 15 (16),Differentiation Purity Assessment - IHC a-actinin (8),Gene Analysis Method - Rare (5),hiPSC-CM Media Supplement - Albumin (28),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Seeding Confluency (%) - 70 to 79 (11),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Cell Line - IMR90 (19),3D Tissue Media - RPMI-1640 (72),Wnt Induction - BMP4 (74),Cell Line - 201B7 (9),3D Tissue Media - RPMI-1640 (72),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Publication Year - 2019 (57),Metabolic Component - Albumax (3),3D Stromal Cell Source - Mesenchymal Stem Cell (12),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Tissue Media - DMEM (53),Cell Coculture - Cardiomyocyte (157),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Cell Line - Cor.4U (16),Calcium Handling Analysis Method - Visual (104),Cell Line - iCell (47),Number of Cell Lines - 4 (11),Journal - Int J Mol Sci (3),Publication Year - 2016 (32),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),hiPSC-CM Maturation Media - iCell Maintenance (83),Journal - Toxicological Sciences (4),Calcium Handling Analysis Method - Visual (104),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Journal - Toxicological Sciences (4),Cell Line - iCell (47),Number of Cell Lines - 3 (29),2D Surface - Decellularized ECM (3),3D Stromal Cell Source - Human Fibroblast (38),Disease Modelling - Arrhythmic (15),Cell Line - Cor.4U (16),Journal - Sci Rep (24),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),hiPSC-CM Purification Duration (days) - 5 days (6),Wnt Inhibitor - Others (9),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Metabolic Component Category - Hormonal Stimulation (14),Electrophysiology Analysis Method - Optical Mapping (39)
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Journal - Acta Biomater (10),Contractile Analysis Method - Force Transducer (27),Seeding Confluency 3D (%) - 95 to 100 (13),Electrophysiology Analysis Method - Patch Clamp (59),Calcium Handling Analysis Method - Seahorse (35),Cell Line - 253G1 (10),Calcium Handling Analysis Method - Visual (104),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Journal - Biosens Bioelectron (4),Wnt Induction - Rare (4),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Coating for Replating - Rare (6),3D Stromal Cell Source - Rare (4),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),3D Tissue Media - RPMI-1640 (72),Maturation Strategy - Other Cells (80),Cell Coculture - Cardiomyocyte (157),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Contractile Analysis Method - Force Transducer (27),Journal - J Mol Cell Cardiol (4),Publication Year - 2014 (3),Journal - Stem Cell Res (8),Seeding Confluency 3D (%) - 85 to 89 (12),Insulin Start Day - 7 (85),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Number of Cell Lines - 4 (11),Sacromere or Cellular Alignment Analysis - Yes (72),Seeding Confluency 3D (%) - 80 to 84 (5),Calcium Handling Analysis Method - Visual (104),Electron Imaging - Scanning (22),Wnt Induction Duration (days) - 3 days (38),hiPSC Backbone Media - DMEM (10),Maturation Strategy - Other Cells (80),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Disease Modelling - Genetic Disorders (18),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Maturation Strategy - Other Cells (80),3D Platform - Fibrin (50),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Cell Coculture - Cardiomyocyte (157),3D Tissue Media - Commercial Kit (21),Electrophysiology Analysis Method - Patch Clamp (59),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Electron Imaging - Transmission (62),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),hiPSC Backbone Media - StemPro-34 (14),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Cell Coculture - Stromal Cell (78),Journal - Biosens Bioelectron (4),Publication Year - 2021 (43),Cell Line - 253G1 (10),Electron Imaging - Scanning (22),Maturation Strategy - Other Cells (80),Calcium Handling Analysis Method - Visual (104),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Calcium Handling Analysis Method - Visual (104),Coating for Replating - Vitronectin (3),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Journal - Rare (104),Journal - Stem Cells (11),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Pharmacological Intervention - QT-Prolonging Drugs (36),Journal - Biosens Bioelectron (4),Pharmacological Intervention - E4031 (22),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Journal - Tissue Eng Part C Methods (6),Journal - Am J Physiol Heart Circ Physiol (4),hiPSC-CM Media Supplement - 1-thioglycerol (14),Cell Line - DF19-9-11T.H (16),Wnt Inhibitor - IWP (112),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),Seeding Confluency (%) - Rare (43),Calcium Handling Analysis Method - Genetical (23),Purification Protocol - Cell Sorting (7),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Metabolic Component - B27 (3),Number of Cell Lines - 3 (29),Maturation Strategy - Cell Alignment (59),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Cell Coculture - Cardiomyocyte (157),hiPSC Backbone Media - Essential 8 (82),3D Tissue Media - DMEM (53),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),hiPSC-CM Maturation Media - iCell Maintenance (83),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),2D Surface - Decellularized ECM (3),hiPSC-CM Maturation Media - iCell Maintenance (83),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Cell Line - iCell (47),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),hiPSC-CM Maturation Media - iCell Maintenance (83),Journal - Biomaterials (16),Cell Line - Cor.4U (16),Journal - Toxicological Sciences (4),Journal - Nat Commun (13),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Journal - Toxicological Sciences (4),Gene Analysis Method - RNA (169),Electrophysiology Analysis Method - Optical Mapping (39),Number of Cell Lines - 3 (29),2D Surface - Microelectrode Array (9),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Cell Line - iCell (47),Seeding Confluency 2D (%) - 85 to 89 (26),Publication Year - 2016 (32),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Journal - Cell Rep (6),Insulin Start Day - 2 (4),Journal - Nano Lett (3)
Journal - Tissue Eng Part C Methods (6),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Day of Insulin Addition - not 22 (12),Journal - Tissue Eng Part C Methods (6),Purification Protocol - Glucose and Lactate (85),Insulin Withdrawal Duration (days) - 3 days (6),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Day of Insulin Addition - not 11 (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Pharmacological Intervention - Cisapride (8),Calcium Handling Analysis Method - Seahorse (35),Journal - Rare (104),hiPSC Backbone Media - Conditioned (12),TNNI3 Precentage (TTNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Number of Cell Lines - 3 (29),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),3D Platform - Scaffold Free (43),Cell Coculture - Cardiomyocyte (157),3D Stromal Cell Source - Human Fibroblast (38),3D Stromal Cell Source - Human Fibroblast (38),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Calcium Handling Analysis Method - Genetical (3),Journal - J Mol Cell Card (6),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Journal - Stem Cells Int (3),hiPSC Backbone Media - Essential 8 (82),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),Metabolic Component Category - Metabolic Modulation (20),3D Platform - Extracellular Scaffold (18),Publication Year - 2018 (45),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Publication Year - 2017 (43),3D Stromal Cell Source - hiPSC-MuralC (3),3D Stromal Cell Source - Human Fibroblast (38),Journal - Nat Biomed Eng (5),Contractile Analysis Method - Rare (7),Pharmacological Intervention - T3 (3),3D Stromal Cell Source - Stromal Cell (35),Maturation Strategy - Tension (64),Seeding Confluency 3D (%) - Rare (26),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC Backbone Media - Commercial CM Kit (12),Journal - Nano Lett (3),Disease Modelling - Arrhythmic (15),Cell Line - IMR90 (19),hiPSC-CM Media Supplement - Selenium (7),3D Tissue Media - MEM-α (60),Metabolic Component - Dexamethasone (7),Coating for Replating - Laminin (5),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Electron Imaging - Transmission (62),Cell Line - DF19-9-11T.H (16),Journal - J Mol Cell Card (6),3D Tissue Media - Iscove (5),2D Surface - Micropatterned (27),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Pharmacological Intervention - Cisapride (8),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),hiPSC-CM Purification Duration (days) - 3 days (13),Seeding Confluency 3D (%) - 70 to 79 (3),Insulin Start Day - 2 (4),Day of Insulin Addition - not 9 (3),Pharmacological Intervention - QT-Prolonging Drugs (36),hiPSC Matrix Coating - Matrigel (163),Pharmacological Intervention - Lidocaine (7),hiPSC Matrix Coating - EBs (18),Pharmacological Intervention - Caffeine (4),hiPSC Matrix Coating - Matrigel (163),Wnt Induction - CHIR99021 (184),Wnt Induction - Activin A (80),Wnt Induction - Activin A (80),hiPSC Matrix Coating - Matrigel (163),Cell Line - Rare (132),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Metabolic Component Category - Fatty Acids and Lipids (21),Publication Year - 2015 (19),Cell Line - PGP1 (11),Journal - Biomaterials (16),Contractile Analysis Method - Motion Tracking (93),3D Tissue Media - DMEM (53),Cell Coculture - Cardiomyocyte (157),Electrophysiology Analysis Method - Patch Clamp (59),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),hiPSC-CM Maturation Media - iCell Maintenance (83),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Number of Cell Lines - 3 (29),Cell Line - Cor.4U (16),Number of Cell Lines - 3 (29),Journal - Toxicological Sciences (4),Publication Year - Late-2010s (196),Journal - Toxicological Sciences (4),hiPSC-CM Purification Duration (days) - 3 days (13),Journal - Lab Chip (4),Electrophysiology Analysis Method - Microelectrode (31),Disease Modelling - Arrhythmic (15),Journal - Int J Mol Sci (3),Insulin Start Day - 6 (20),Contractile Analysis Method - Deflection (39),Cell Line - Cor.4U (16),Number of Cell Lines - 3 (29),Number of Cell Lines - 3 (29),Number of Cell Lines - >5 (9),Cell Line - SCVI-273 (8),Electrophysiology Analysis Method - Microelectrode (31),Day of Insulin Addition - not 25 (3),2D Surface - Hydrogel (17),Wnt Inhibitor - Wnt-C59 (30),3D Platform - Nanotechnology (3)
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Wnt Inhibitor - IWP (112),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Journal - Nano Lett (3),Coating for Replating - Gelatin (43),Calcium Handling Analysis Method - Visual (104),Maturation Strategy - ECM (21),2D Surface - Nanotopography (6),Pharmacological Intervention - E4031 (22),Maturation Strategy - Other Cells (80),Contractile Analysis Method - Rare (7),Seeding Confluency 2D (%) - 70 to 79 (6),Insulin Withdrawal Duration (days) - 4 days (18),3D Platform - Fibrin (50),Deduced Culture Strategy - 3D Only (157),Cell Coculture - Endothelial Cell (35),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Cell Line Ancestry - Caucasian (41),Publication Year - 2018 (45),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),hiPSC Matrix Coating - Matrigel (163),hiPSC Matrix Coating - Matrigel (163),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Contractile Analysis Method - Deflection (39),Coating for Replating - Fibronectin (32),Coating for Replating - Rare (6),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Differentiation Purity Assessment - IHC cTnT (7),Maturation Strategy - Electrical (39),Wnt Inhibitor - XAV939 (24),Journal - Nano Lett (3),Publication Year - 2018 (45),Journal - Tissue Eng Part A (4),Publication Year - 2019 (57),Maturation Strategy - Cell Alignment (59),Cell Coculture - Cardiomyocyte (157),Cell Coculture - Stromal Cell (78),3D Platform - Scaffold Free (43),3D Tissue Media - Growth Factor (12),Cell Coculture - Cardiomyocyte (157),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),2D Surface - Micropatterned (27),Number of Cell Lines - 2 (50),Fatty Acid Metabolism Assessed - Yes (20),Journal - J Tissue Eng Regen Med (3),hiPSC-CM Media Supplement - Lipid Mix (5),3D Tissue Media - DMEM (53),Seeding Confluency 3D (%) - 90 to 94 (13),Contractile Analysis Method - Force Transducer (27),Cell Line Sex - Both (118),Insulin Start Day - 7 (85),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Calcium Handling Analysis Method - Visual (104),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Pharmacological Intervention - Adrenaline (83),Cell Line Sex - Both (118),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),hiPSC Backbone Media - mTeSR (106),Journal - Am J Physiol Heart Circ Physiol (4),2D Surface - Decellularized ECM (3),2D Surface - Micropatterned (27),Coating for Replating - Gelatin (43),Cell Line - C25 (6),Purification Protocol - Cell Sorting (7),Seeding Confluency (%) - Rare (43),Cell Line - C25 (6),Calcium Handling Analysis Method - Seahorse (35),hiPSC Backbone Media - Embryonic Stem Cell (127),Cell Line - PGP1 (11),Seeding Confluency (%) - Rare (43),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),Publication Year - 2022 (20),Electrophysiology Analysis Method - Patch Clamp (59),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Maturation Strategy - Metabolic (33),Insulin Start Day - 7 (85),hiPSC Backbone Media - iCell Maintenance (86),Journal - Nat Commun (13),Gene Analysis Method - RNA (169),Contractile Analysis Method - Deflection (39),Publication Year - 2016 (32),Coating for Replating - Gelatin (43),hiPSC Backbone Media - iCell Maintenance (86),Electron Imaging - Scanning (22),Number of Cell Lines - 3 (29),Maturation Strategy - ECM (21),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),hiPSC-CM Maturation Media - iCell Maintenance (83),Coating for Replating - Matrigel (65),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Number of Cell Lines - 3 (29),Coating for Replating - Rare (6),Electrophysiology Analysis Method - Microelectrode (31),hiPSC Backbone Media - iCell Maintenance (86),Electrophysiology Analysis Method - Microelectrode (31),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),3D Tissue Media - Commercial Kit (21),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Maturation Strategy - ECM (21),hiPSC Backbone Media - iCell Maintenance (86),Differentiation Purity Assessment - IHC a-actinin (8),Journal - Acta Biomater (10),Wnt Inhibitor Duration (days) - 4 days (19),Calcium Handling Analysis Method - Visual (104),hiPSC-CM Maturation Media - iCell Maintenance (83),hiPSC-CM Maturation Media - iCell Maintenance (83),Wnt Inhibitor - bFGF (8),2D Surface - Microelectrode Array (9)
Calcium Handling Analysis Method - Seahorse (35),Gene Analysis Method - RNA (169),Journal - Circulation (11),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Metabolic Component - Fatty Acid (13),Pharmacological Intervention - Adrenaline (83),hiPSC Matrix Coating - Geltrex (33),Journal - PNAS (3),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Cell Coculture - Endothelial Cell (35),Disease Modelling - Arrhythmic (15),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Journal - Tissue Eng Part A (4),Seeding Confluency 3D (%) - Rare (26),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Deduced Culture Strategy - 3D Only (157),Cell Line - BJ1 (7),Publication Year - 2021 (43),Calcium Handling Analysis Method - Visual (104),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Contractile Analysis Method - Force Transducer (27),Gene Analysis Method - RNA (169),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Cell Line - IMR90 (19),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),3D Tissue Media - iCell Maintenance (12),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),hiPSC Backbone Media - Rare (19),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),hiPSC-CM Maturation Media - StemPro-34 (14),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Journal - Tissue Eng Part A (4),Disease Modelling - Arrhythmic (15),3D Stromal Cell Source - Human Fibroblast (38),Contractile Analysis Method - Deflection (39),3D Platform - Fibrin (50),3D Tissue Media - iCell Maintenance (12),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),hiPSC-CM Purification Duration (days) - <3 days (31),Disease Modelling - Dilated Cardiomyopathy (6),3D Platform - Polyethylene Glycol (8),Insulin Start Day - 7 (85),Cell Line - 201B7 (9),3D Tissue Media - MEM-α (60),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),3D Tissue Media - RPMI-1640 (72),Wnt Induction - Activin A (80),Publication Year - Post 2020 (122),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),3D Tissue Media - MEM-α (60),3D Platform - Scaffold Free (43),Maturation Strategy - ECM (21),Calcium Handling Analysis Method - Visual (104),Metabolic Component Category - Signaling Pathway Regulators (6),hiPSC Matrix Coating - Vitronectin (10),Pharmacological Intervention - Isoproterenol (71),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Journal - Stem Cells Int (3),Electrophysiology Analysis Method - Optical Mapping (39),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Number of Cell Lines - 4 (11),hiPSC Matrix Coating - EBs (18),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Wnt Induction - BMP4 (74),Cell Line - 201B7 (9),Day of Insulin Addition - Known (177),Seeding Confluency 2D (%) - Rare (13),Cell Line Sex - Male (64),Day of Insulin Addition - not 20 (15),Electrophysiology Analysis Method - Genetical (3),Calcium Handling Analysis Method - Visual (104),New Media for Maturation - DMEM (21),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Journal - ACS Appl Mater Interfaces (4),Differentiation Purity Assessment - Visual Inspection (6),Publication Year - 2016 (32),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Electrophysiology Analysis Method - Optical Mapping (39),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Cell Line - iCell2 (8),Cell Line - iCell (47),Seeding Confluency 2D (%) - 80 to 84 (5),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),Journal - Toxicological Sciences (4),hiPSC Backbone Media - iCell Maintenance (86),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Electrophysiology Analysis Method - Optical Mapping (39),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Calcium Handling Analysis Method - Visual (104),Journal - Lab Chip (4),2D Surface - Microelectrode Array (9),Journal - Acta Biomater (10),Journal - Sci Rep (24),3D Stromal Cell Source - Cardiac Fibroblast (32),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Insulin Start Day - 5 (14),hiPSC Matrix Coating - Vitronectin (10),hiPSC-CM Media Supplement - HEPES (16),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),hiPSC-CM Maturation Media - F12 (10),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)
hiPSC-CM Media Supplement - Rare (5),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),Number of Cell Lines - 3 (29),Purification Protocol - Glucose and Lactate (85),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Coating for Replating - Matrigel (65),Purification Protocol - Metabolic (8),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Publication Year - 2017 (43),Cell Line - BJ RiPS (4),Pharmacological Intervention - QT-Prolonging Drugs (36),Electron Imaging - Transmission (62),Number of Cell Lines - 3 (29),3D Platform - Collagen (38),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),3D Stromal Cell Source - Cardiac Fibroblast (32),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),3D Stromal Cell Source - Cardiac Fibroblast (32),Journal - Biomaterials (16),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Cell Line - Gibco episomal (10),2D Surface - Micropatterned (27),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),hiPSC-CM Purification Duration (days) - 3 days (13),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Journal - Biomaterials (16),Seeding Confluency (%) - 80 to 84 (12),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Journal - Cell Stem Cell (6),Seeding Confluency 2D (%) - 85 to 89 (26),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),Journal - Lab Chip (4),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Disease Modelling - Arrhythmic (15),Metabolic Component Category - Fatty Acids and Lipids (21),Deduced Culture Strategy - 3D Only (157),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),3D Tissue Media - RPMI-1640 (72),Cell Coculture - Endothelial Cell (35),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Sacromere or Cellular Alignment Analysis - Yes (72),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),hiPSC-CM Purification Duration (days) - 6 days (10),hiPSC Backbone Media - Embryonic Stem Cell (127),hiPSC Backbone Media - DMEM (18),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),Contractile Analysis Method - Deflection (39),Cell Line - 201B6 (3),Pharmacological Intervention - Verapamil (27),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Coating for Replating - Rare (6),Metabolic Component - IGF-1 (3),hiPSC Backbone Media - mTeSR (106),Calcium Handling Analysis Method - Genetical (23),Publication Year - 2018 (45),Calcium Handling Analysis Method - Visual (104),Seeding Confluency (%) - 90 to 94 (26),Disease Modelling - Dilated Cardiomyopathy (6),3D Stromal Cell Source - Dermal Fibroblast (7),Metabolic Component - Insulin-Transferrin-Selenium (3),Journal - Nano Lett (3),Wnt Induction Duration (days) - 3 days (38),Electrophysiology Analysis Method - Microelectrode (31),Calcium Handling Analysis Method - Genetical (23),Coating for Replating - Laminin (5),Wnt Inhibitor - Wnt-C59 (30),Cell Line - PGP1 (11),hiPSC Matrix Coating - Matrigel (163),3D Stromal Cell Source - hiPSC-MuralC (3),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),Maturation Strategy - Tension (64),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Differentiation Purity Assessment - Rare (3),Wnt Inhibitor - BMP4 (7),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Number of Cell Lines - 2 (50),Electrophysiology Analysis Method - Optical Mapping (39),Publication Year - 2016 (32),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Publication Year - 2016 (32),Electron Imaging - Scanning (22),2D Surface - Decellularized ECM (3),Cell Line - Cor.4U (16),3D Stromal Cell Source - Cardiac Fibroblast (32),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Contractile Analysis Method - Deflection (39),Cell Line - iCell (47),Journal - Nat Commun (13),Publication Year - 2019 (57),2D Surface - ECM-coated (115),Disease Modelling - Ischemic Infarction (9),Journal - Cell Rep (6),Number of Cell Lines - >5 (9),Publication Year - 2019 (57),Coating for Replating - Matrigel (65),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Calcium Handling Analysis Method - Genetical (23),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Wnt Inhibitor - Others (9),3D Platform - Polyethylene Glycol (8),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Coating for Replating - Gelatin (43),Cell Line - Cellapy (4),Journal - Rare (104)
Publication Year - 2019 (57),Insulin Start Day - 6 (20),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Number of Cell Lines - 2 (50),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Publication Year - 2017 (43),Journal - Biomaterials (16),2D Surface - Hydrogel (17),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Maturation Strategy - ECM (21),Calcium Handling Analysis Method - Visual (104),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Platform - Fibrin (50),Cell Line Sex - Female (40),2D Surface - ECM-coated (115),Electrophysiology Analysis Method - Patch Clamp (59),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Publication Year - 2017 (43),Seeding Confluency (%) - 85 to 89 (43),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Pharmacological Intervention - Isoproterenol (71),Metabolic Component - Palmitic Acid (11),Journal - Tissue Eng Part A (4),Journal - Tissue Eng Part A (4),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Number of Cell Lines - 2 (50),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Insulin Start Day - 10 (6),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Insulin Start Day - 0 (7),3D Platform - Collagen (38),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Electron Imaging - Transmission (62),Journal - Acta Biomater (10),Metabolic Component - T3 (14),Calcium Handling Analysis Method - Visual (104),Cell Line - IMR90 (19),Publication Year - 2018 (45),hiPSC-CM Maturation Media - StemPro-34 (14),3D Platform - Fibrin (50),3D Stromal Cell Source - Dermal Fibroblast (7),Wnt Induction - Wnt3a (3),Differentiation Purity Assessment - IHC cTnT (7),2D Surface - Micropatterned (27),Calcium Handling Analysis Method - Flux Rates (13),Publication Year - 2015 (19),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),hiPSC Backbone Media - Essential 8 (82),Seeding Confluency 3D (%) - 90 to 94 (13),Calcium Handling Analysis Method - Rare (4),hiPSC-CM Media Supplement - Polyvinylalchohol (6),hiPSC-CM Media Supplement - Mercaptoethanol (10),Publication Year - 2014 (3),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Wnt Induction - Rare (4),hiPSC Matrix Coating - Geltrex (33),Wnt Inhibitor Duration (days) - 5 days (6),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Wnt Inhibitor - IWP (112),hiPSC Backbone Media - mTeSR (106),Wnt Induction - Wnt3a (3),Cell Line - C25 (6),Day of Insulin Addition - not 21 (14),Journal - Am J Physiol Heart Circ Physiol (4),Electrophysiology Analysis Method - Patch Clamp (59),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Contractile Analysis Method - Deflection (39),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Cell Line - Cellapy (4),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Cell Line - Cellapy (4),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Cell Coculture - Endothelial Cell (35),hiPSC Backbone Media - iCell Maintenance (86),Cell Line - iCell (47),Disease Modelling - Ischemic Infarction (9),Coating for Replating - Matrigel (65),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),hiPSC-CM Maturation Media - iCell Maintenance (83),Journal - Cell Rep (6),hiPSC-CM Maturation Media - Cor.4U Complete (6),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Cell Line - 253G1 (10),Seeding Confluency 3D (%) - 95 to 100 (13),Coating for Replating - Rare (6),Coating for Replating - Matrigel (65),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)
Cell Line - Cellapy (4),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),hiPSC-CM Purification Duration (days) - <3 days (31),Insulin Start Day - 7 (85),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Metabolic Component Category - Metabolic Modulation (20),hiPSC-CM Purification Duration (days) - <3 days (31),Maturation Strategy - ECM (21),hiPSC Backbone Media - DMEM (10),Journal - Circ Res (5),Sacromere or Cellular Alignment Analysis - Yes (72),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),hiPSC-CM Media Supplement - Polyvinylalchohol (6),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Publication Year - 2019 (57),Insulin Start Day - 6 (20),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Stromal Cell Source - Stromal Cell (35),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),3D Stromal Cell Source - hiPSC-MuralC (3),Publication Year - 2022 (20),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Maturation Strategy - Tension (64),Purification Protocol - Glucose and Lactate (85),Wnt Induction - BMP4 (74),hiPSC Backbone Media - StemFit (5),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Publication Year - 2022 (20),3D Tissue Media - iCell Maintenance (12),Cell Line - BJ1 (7),Wnt Induction Duration (days) - 3 days (38),hiPSC-CM Media Supplement - Ascorbic Acid (41),3D Stromal Cell Source - Dermal Fibroblast (7),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),3D Stromal Cell Source - Cardiac Fibroblast (32),3D Tissue Media - RPMI-1640 (72),Maturation Strategy - Tension (64),Journal - Rare (104),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Deduced Culture Strategy - 2D Only (183),Insulin Start Day - 7 (85),Electrophysiology Analysis Method - Patch Clamp (59),hiPSC-CM Maturation Media - DMEM (35),hiPSC-CM Media Supplement - Transferrin (11),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),3D Stromal Cell Source - Cardiac Fibroblast (32),hiPSC-CM Purification Duration (days) - 4 days (29),Journal - Biomaterials (16),2D Surface - Decellularized ECM (3),Publication Year - 2024 (7),Journal - Tissue Eng Part A (4),Metabolic Component - T3 (14),Wnt Induction - StemCell Diff Kit (4),hiPSC Backbone Media - StemFlex (5),Wnt Inhibitor - IWR (56),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),hiPSC-CM Media Supplement - GlutaMax (8),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Cell Line - iCell (47),Pharmacological Intervention - Other Antiarrhythmic Agents (13),Seeding Confluency 2D (%) - 70 to 79 (6),Journal - Nat Commun (13),Wnt Induction - CHIR99021 (184),hiPSC Backbone Media - Embryonic Stem Cell (127),Insulin Start Day - 5 (14),Publication Year - 2018 (45),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Cell Line - iCell (47),hiPSC-CM Purification Duration (days) - 4 days (29),Journal - Tissue Eng Part A (4),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),hiPSC-CM Maturation Media - iCell Maintenance (83),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Electrophysiology Analysis Method - Optical Mapping (39),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),2D Surface - Decellularized ECM (3),Cell Line - Cellapy (4),3D Platform - Scaffold Free (43),hiPSC-CM Media Supplement - HEPES (16),Electron Imaging - Transmission (62),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Contractile Analysis Method - Motion Tracking (93),hiPSC-CM Maturation Media - iCell Maintenance (83),Journal - Sci Rep (24),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Cell Line - Rare (132),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Wnt Inhibitor Duration (days) - >6 days (12),3D Tissue Media - Iscove (5),Insulin Start Day - 11 (3),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Number of Cell Lines - 4 (11),Electrophysiology Analysis Method - Optical Mapping (39),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Insulin Withdrawal Duration (days) - 6 days (3),Number of Cell Lines - 3 (29),Insulin Start Day - After 11 (7),3D Stromal Cell Source - hiPSC-CardiacF (8)
TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Calcium Handling Analysis Method - Seahorse (35),3D Stromal Cell Source - Human Fibroblast (38),Maturation Strategy - Tension (64),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),hiPSC Backbone Media - mTeSR (106),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Wnt Inhibitor - VEGF (3),Metabolic Component Category - Signaling Pathway Regulators (6),Purification Protocol - Metabolic (8),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),3D Stromal Cell Source - Human Fibroblast (38),Seeding Confluency 3D (%) - 85 to 89 (12),Pharmacological Intervention - Doxorubicin (17),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),Seeding Confluency (%) - 90 to 94 (26),3D Platform - Fibrin (50),Seeding Confluency (%) - 70 to 79 (11),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),hiPSC Matrix Coating - Vitronectin (10),Pharmacological Intervention - Carbamylcholine (6),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Cell Line - Gibco episomal (10),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),Seeding Confluency (%) - 85 to 89 (43),Wnt Induction - BMP4 (74),hiPSC-CM Media Supplement - L-glutamine (19),Sacromere or Cellular Alignment Analysis - Yes (72),Disease Modelling - Ischemic Infarction (9),Maturation Strategy - Mechanical (36),3D Endothelial Cell Source - hiPSC-EndothelialC (16),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Maturation Strategy - Other Cells (80),2D Surface - ECM-coated (115),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Calcium Handling Analysis Method - Mitochondrial (4),3D Platform - Fibrin (50),Seeding Confluency (%) - Rare (43),hiPSC-CM Media Supplement - HEPES (16),Pharmacological Intervention - Adrenaline (83),Cell Coculture - Stromal Cell (78),Wnt Induction Duration (days) Quantiles - Q2 (>1 and ≤2) (75),3D Tissue Media - DMEM (53),Sacromere or Cellular Alignment Analysis - Yes (72),Sacromere or Cellular Alignment Analysis - Yes (72),Publication Year - 2018 (45),Journal - Circ Res (5),Metabolic Component Category - Kinase Inhibitors (3),Seeding Confluency 3D (%) - 80 to 84 (5),Contractile Analysis Method - Deflection (39),Cell Line Sex - Both (118),Pharmacological Intervention - Cisapride (8),Cell Line Ancestry - Caucasian (41),3D Stromal Cell Source - hiPSC-SmoothMC (3),Cell Line - BJ1 (7),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),2D Surface - Microelectrode Array (9),hiPSC Backbone Media - RPMI-1640 (167),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Day of Insulin Addition - Known (177),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),hiPSC-CM Media Supplement - Lipids (9),Wnt Induction - bFGF (45),Day of Insulin Addition - Known (177),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Electrophysiology Analysis Method - Genetical (3),Insulin Start Day - 9 (10),hiPSC Matrix Coating - MEF feeder cells (8),Journal - Circulation (11),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),3D Tissue Media - MEM-α (60),3D Tissue Media - MEM-α (60),3D Tissue Media - MEM-α (60),3D Platform - Extracellular Scaffold (18),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),2D Surface - ECM-coated (115),Wnt Inhibitor Duration (days) - 4 days (19),3D Tissue Media - Commercial Kit (21),3D Tissue Media - Rare (13),Publication Year - 2020 (51),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Wnt Inhibitor - DS-I-7 (9),hiPSC Backbone Media - iCell Maintenance (86),Maturation Strategy - Electrical (39),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Coating for Replating - Gelatin (43),Coating for Replating - Gelatin (43),hiPSC Backbone Media - Commercial CM Kit (12),Coating for Replating - Gelatin (43),Publication Year - 2020 (51),Journal - Toxicological Sciences (4),Number of Cell Lines - 2 (50),Journal - Cell Stem Cell (6),2D Surface - Electrospun (13),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),hiPSC-CM Purification Duration (days) - 5 days (6),Coating for Replating - Gelatin (43)
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Cell Line - Cellapy (4),3D Tissue Media - Growth Factor (12),Pharmacological Intervention - Isoproterenol (71),Purification Protocol - Glucose and Lactate (85),Metabolic Component Category - Fatty Acids and Lipids (21),Seeding Confluency 3D (%) - 95 to 100 (13),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Differentiation Purity Assessment - IHC cTnT (7),Coating for Replating - Fibronectin (32),Contractile Analysis Method - Force Transducer (27),Number of Cell Lines - 3 (29),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),3D Platform - Matrigel (33),2D Surface - ECM-coated (115),Pharmacological Intervention - T3 (3),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),,3D Platform - 3D printed (9),3D Platform - Collagen (38),Insulin Start Day - 1 (19),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),Calcium Handling Analysis Method - Rare (4),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Journal - Stem Cell Reports (23),3D Platform - Collagen (38),Maturation Strategy - Cell Alignment (59),Maturation Strategy - Tension (64),hiPSC Matrix Coating - Geltrex (33),Calcium Handling Analysis Method - Genetical (23),2D Surface - Decellularized ECM (3),Electron Imaging - Scanning (22),hiPSC-CM Purification Duration (days) - 6 days (10),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Cell Coculture - Stromal Cell (78),hiPSC-CM Purification Duration (days) - 3 days (13),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),Maturation Strategy - Other Cells (80),Seeding Confluency 3D (%) - 85 to 89 (12),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Contractile Analysis Method - Motion Tracking (93),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Wnt Inhibitor Duration (days) - 5 days (6),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Seeding Confluency (%) - 70 to 79 (11),Maturation Strategy - Other Cells (80),Insulin Start Day - 6 (20),Deduced Culture Strategy - 3D Only (157),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),3D Endothelial Cell Source - hiPSC-EndothelialC (16),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Journal - Tissue Eng Part A (4),Journal - ACS Appl Mater Interfaces (4),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),New Media for Maturation - Commercial Kit (5),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Cell Line - IMR90 (19),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),Insulin Start Day - 7 (85),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),hiPSC Backbone Media - mTeSR (106),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Wnt Inhibitor - Rare (3),hiPSC-CM Media Supplement - Lipids (9),hiPSC-CM Media Supplement - Lipids (9),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Wnt Inhibitor Duration (days) - Rare (173),Purification Protocol - Glucose and Lactate (85),Journal - Stem Cell Res (8),Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC-CM Purification Duration (days) - 4 days (29),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Journal - Am J Physiol Heart Circ Physiol (4),Pharmacological Intervention - Epinephrine (11),Journal - Cell Stem Cell (6),Pharmacological Intervention - Lidocaine (7),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),3D Stromal Cell Source - Human Fibroblast (38),Electrophysiology Analysis Method - Optical Mapping (39),Contractile Analysis Method - Motion Tracking (93),hiPSC Backbone Media - iCell Maintenance (86),Calcium Handling Analysis Method - Visual (104),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Electron Imaging - Scanning (22),hiPSC Backbone Media - iCell Maintenance (86),Cell Coculture - Endothelial Cell (35),2D Surface - ECM-coated (115),3D Platform - Polyethylene Glycol (8),hiPSC Backbone Media - Rare (19),Coating for Replating - Matrigel (65),2D Surface - ECM-coated (115),Journal - Toxicological Sciences (4),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Number of Cell Lines - 2 (50),Calcium Handling Analysis Method - Visual (104),Disease Modelling - Fibrotic (4),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),2D Surface - Microelectrode Array (9),Publication Year - 2017 (43),Differentiation Purity Assessment - IHC cTnT (7),Cell Line - DF19-9-11T.H (16),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Maturation Strategy - Elastomeric (33),hiPSC-CM Media Supplement - Albumin (28),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)
3D Tissue Media - RPMI-1640 (72),Wnt Induction Duration (days) - 3 days (38),hiPSC Backbone Media - Conditioned (12),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Metabolic Component - Palmitic Acid (11),Electrophysiology Analysis Method - Optical Mapping (39),Differentiation Purity Assessment - Visual Inspection (6),Journal - Stem Cells (11),Journal - Biomater Sci (7),Journal - Acta Biomater (10),Pharmacological Intervention - Isoproterenol (71),Metabolic Component Category - Kinase Inhibitors (3),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Publication Year - 2022 (20),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Disease Modelling - Ischemic Infarction (9),,3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),3D Stromal Cell Source - Cardiac Fibroblast (32),3D Tissue Media - DMEM (53),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Pharmacological Intervention - T3 (3),Cell Line - WTC11 (30),3D Tissue Media - RPMI-1640 (72),hiPSC-CM Purification Duration (days) - <3 days (31),2D Surface - Micropatterned (27),Electron Imaging - Scanning (22),Disease Modelling - Fibrotic (4),Metabolic Component Category - Signaling Pathway Regulators (6),Cell Line - iCell2 (8),3D Tissue Media - High-glucose DMEM (9),Coating for Replating - Gelatin (43),Insulin Start Day - 4 (11),Seeding Confluency 3D (%) - 70 to 79 (3),Gene Analysis Method - RNA (169),3D Stromal Cell Source - Dermal Fibroblast (7),Calcium Handling Analysis Method - Seahorse (35),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Platform - Collagen (38),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),3D Tissue Media - MEM-α (60),Journal - Rare (104),Maturation Strategy - Mechanical (36),TNNI3 Precentage (TTNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Journal - Acta Biomater (10),Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC-CM Maturation Media - F12 (10),hiPSC-CM Media Supplement - Polyvinylalchohol (6),Journal - Stem Cell Reports (23),3D Platform - Extracellular Scaffold (18),Publication Year - 2021 (43),Day of Insulin Addition - not 21 (14),Contractile Analysis Method - Motion Tracking (93),Journal - Acta Biomater (10),3D Stromal Cell Source - Stromal Cell (35),Journal - Nat Biomed Eng (5),hiPSC Backbone Media - Commercial CM Kit (12),hiPSC-CM Purification Duration (days) - 5 days (6),Coating for Replating - Matrigel (65),Journal - Biomaterials (16),Maturation Strategy - Electrical (39),Insulin Start Day - 1 (19),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Maturation Strategy - Mechanical (36),Pharmacological Intervention - Carbenoxolone (4),Number of Cell Lines - 3 (29),Seeding Confluency (%) - 70 to 79 (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Maturation Strategy - Metabolic (33),hiPSC Backbone Media - mTeSR (106),hiPSC-CM Media Supplement - B27 (180),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Wnt Induction - Wnt3a (3),hiPSC Backbone Media - Essential 8 (82),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Insulin Start Day - 11 (3),Cell Coculture - Endothelial Cell (35),3D Platform - Collagen (38),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),Deduced Culture Strategy - 3D Only (157),hiPSC Matrix Coating - Geltrex (33),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Number of Cell Lines - 4 (11),Journal - Sci Rep (24),hiPSC Backbone Media - iCell Maintenance (86),Seeding Confluency (%) - 80 to 84 (12),Journal - Stem Cell Reports (23),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Journal - Tissue Eng Part C Methods (6),Insulin Withdrawal Duration (days) - 8 days (3),Cell Line - DF19-9-11T.H (16),Cell Line - iCell2 (8),3D Tissue Media - Rare (13),Electrophysiology Analysis Method - Optical Mapping (39),hiPSC-CM Media Supplement - Rare (5),Disease Modelling - Arrhythmic (15),Wnt Inhibitor Duration (days) - >6 days (12),Cell Line - iCell (47),Wnt Induction - Rare (4),Journal - Toxicological Sciences (4),Differentiation Purity Assessment - Visual Inspection (6),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),hiPSC-CM Purification Duration (days) - 5 days (6),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Day of Insulin Addition - not 9 (3),Publication Year - 2021 (43),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Differentiation Purity Assessment - IHC a-actinin (8)
Metabolic Component - Palmitic Acid (11),2D Surface - ECM-coated (115),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Day of Insulin Addition - not 23 (10),Journal - Sci Transl Med (3),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Contractile Analysis Method - Deflection (39),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Disease Modelling - Rare (4),Electrophysiology Analysis Method - Optical Mapping (39),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Cell Line - C25 (6),Wnt Inhibitor - VEGF (3),Maturation Strategy - Cell Alignment (59),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),,3D Stromal Cell Source - Cardiac Fibroblast (32),Maturation Strategy - Tension (64),Seeding Confluency 3D (%) - 85 to 89 (12),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Publication Year - 2024 (7),Pharmacological Intervention - Caffeine (4),Coating for Replating - Vitronectin (3),Maturation Strategy - Elastomeric (33),Pharmacological Intervention - Other Antiarrhythmic Agents (13),Maturation Strategy - Other Cells (80),Cell Line Sex - Both (118),Calcium Handling Analysis Method - Seahorse (35),Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Platform - Scaffold Free (43),hiPSC-CM Purification Duration (days) - 3 days (13),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Wnt Induction Duration (days) - 4 days (15),Calcium Handling Analysis Method - Seahorse (35),3D Stromal Cell Source - Stromal Cell (35),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Maturation Strategy - Tension (64),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Publication Year - 2021 (43),Cell Line - WTC11 (30),Wnt Induction Duration (days) Quantiles - Q2 (>1 and ≤2) (75),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Journal - J Mol Cell Cardiol (4),hiPSC Matrix Coating - MEF feeder cells (8),3D Tissue Media - DMEM (53),3D Platform - Extracellular Scaffold (18),Cell Line - WTC11 (30),Cell Line Sex - Female (40),Journal - Nat Commun (13),Calcium Handling Analysis Method - Visual (104),Calcium Handling Analysis Method - Rare (4),Cell Line - 253G1 (10),Seeding Confluency 2D (%) - 90 to 94 (12),Contractile Analysis Method - Motion Tracking (93),Maturation Strategy - Elastomeric (33),3D Stromal Cell Source - Rare (4),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Cell Coculture - Stromal Cell (78),Gene Analysis Method - Rare (5),Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Journal - J Mol Cell Cardiol (4),Cell Line Sex - Both (118),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Wnt Induction - Activin A (80),Insulin Start Day - 3 (5),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Publication Year - 2021 (43),Wnt Inhibitor Duration (days) - Rare (173),hiPSC-CM Media Supplement - L-glutamine (19),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),3D Platform - Matrigel (33),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),3D Platform - Matrigel (33),hiPSC-CM Purification Duration (days) - 5 days (6),3D Stromal Cell Source - Human Fibroblast (38),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Maturation Strategy - ECM (21),3D Platform - Scaffold Free (43),Number of Cell Lines - 4 (11),Publication Year - 2017 (43),3D Stromal Cell Source - Human Fibroblast (38),2D Surface - Electrospun (13),Publication Year - 2016 (32),Publication Year - 2020 (51),Journal - Nat Commun (13),Number of Cell Lines - 4 (11),Number of Cell Lines - 4 (11),Publication Year - 2020 (51),Cell Coculture - Endothelial Cell (35),Insulin Start Day - 1 (19),hiPSC Backbone Media - Cor.4U Complete (6),Contractile Analysis Method - Deflection (39),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Journal - Cell Rep (6),Coating for Replating - Rare (6),Wnt Inhibitor - KY02111 (7),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Wnt Inhibitor - bFGF (8),Wnt Inhibitor - BMP4 (7),Publication Year - 2020 (51),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Purification Protocol - Cell Sorting (7),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6)
hiPSC-CM Media Supplement - GlutaMax (8),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),3D Platform - Collagen (38),Day of Insulin Addition - not 20 (15),Contractile Analysis Method - Motion Tracking (93),Publication Year - 2015 (19),Wnt Inhibitor - IWR (56),Seeding Confluency 2D (%) - 70 to 79 (6),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Publication Year - 2016 (32),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Coating for Replating - Matrigel (65),2D Surface - Nanotopography (6),Seeding Confluency 3D (%) - 95 to 100 (13),Maturation Strategy - Tension (64),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),3D Tissue Media - RPMI-1640 (72),,3D Stromal Cell Source - Human Fibroblast (38),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Seeding Confluency 3D (%) - 90 to 94 (13),Cell Line - 201B6 (3),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Seeding Confluency (%) - 90 to 94 (26),Gene Analysis Method - Rare (5),hiPSC-CM Media Supplement - Ascorbic Acid (41),hiPSC-CM Media Supplement - GlutaMax (8),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Pharmacological Intervention - Lidocaine (7),Journal - Cell Stem Cell (6),Cell Line Ancestry - Asian (28),2D Surface - Electrospun (13),Publication Year - 2017 (43),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),hiPSC Backbone Media - Conditioned (12),Calcium Handling Analysis Method - Rare (4),Day of Insulin Addition - not 21 (14),Publication Year - 2019 (57),3D Platform - Matrigel (33),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Endothelial Cell Source - hiPSC-EndothelialC (16),Electron Imaging - Transmission (62),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),hiPSC Backbone Media - Conditioned (12),hiPSC-CM Media Supplement - FBS (16),hiPSC-CM Maturation Media - iCell Maintenance (83),Pharmacological Intervention - Propranolol (5),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Seeding Confluency 3D (%) - Rare (26),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Journal - ACS Biomater Sci Eng (3),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),3D Stromal Cell Source - Rare (4),Journal - Nano Lett (3),Journal - Tissue Eng Part A (4),Pharmacological Intervention - Carbamylcholine (6),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Maturation Strategy - Other Cells (80),Cell Line - BJ RiPS (4),Publication Year - 2024 (7),Insulin Start Day - 10 (6),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Contractile Analysis Method - Deflection (39),2D Surface - Microelectrode Array (9),hiPSC Backbone Media - DMEM (10),New Media for Maturation - Commercial Kit (5),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Insulin Start Day - After 11 (7),Metabolic Component - Palmitic Acid (11),Wnt Induction - Activin A (80),Cell Line Ancestry - Caucasian (41),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Seeding Confluency 2D (%) - Rare (13),Day of Insulin Addition - not 22 (12),hiPSC-CM Purification Duration (days) - 4 days (29),3D Platform - Extracellular Scaffold (18),Metabolic Component - Biotin (3),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - Circ Res (5),Insulin Start Day - After 11 (7),3D Stromal Cell Source - Cardiac Fibroblast (32),3D Tissue Media - Growth Factor (12),hiPSC Matrix Coating - Geltrex (33),Journal - Toxicological Sciences (4),Journal - Nat Commun (13),hiPSC-CM Maturation Media - Rare (9),Contractile Analysis Method - Motion Tracking (93),Number of Cell Lines - 4 (11),Cell Line - 253G1 (10),Journal - Nat Commun (13),Journal - Nat Commun (13),hiPSC-CM Purification Duration (days) - 8 days (4),Publication Year - 2016 (32),Journal - Cell Rep (6),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),hiPSC Backbone Media - iCell Maintenance (86),Number of Cell Lines - 4 (11),hiPSC-CM Media Supplement - Polyvinylalchohol (6),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),hiPSC Backbone Media - iCell Maintenance (86),3D Platform - Nanotechnology (3),Number of Cell Lines - 4 (11),Publication Year - 2019 (57),Cell Line - C25 (6),Electron Imaging - Transmission (62),2D Surface - Nanotopography (6),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Publication Year - 2019 (57),Publication Year - 2020 (51)
Insulin Start Day - 6 (20),Seeding Confluency 2D (%) - 80 to 84 (5),Insulin Start Day - 11 (3),Wnt Inhibitor - IWP (112),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Metabolic Component Category - Sugars and Carbohydrates (9),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Wnt Inhibitor - IWR (56),Pharmacological Intervention - E4031 (22),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Metabolic Component - Lactate (4),Electrophysiology Analysis Method - Patch Clamp (59),Insulin Start Day - 6 (20),Calcium Handling Analysis Method - Rare (4),Gene Analysis Method - RNA (169),,3D Stromal Cell Source - hiPSC-MuralC (3),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Contractile Analysis Method - Deflection (39),Seeding Confluency 3D (%) - 70 to 79 (3),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Calcium Handling Analysis Method - Seahorse (35),Cell Line - DF19-9-11T.H (16),Maturation Strategy - Mechanical (36),Cell Line - ATCC (5),hiPSC-CM Maturation Media - iCell Maintenance (83),Metabolic Component - IGF-1 (3),Electron Imaging - Transmission (62),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Journal - ACS Appl Mater Interfaces (4),Metabolic Component - Fatty Acid (13),2D Surface - Microelectrode Array (9),hiPSC-CM Maturation Media - Commercial Kit (27),Seeding Confluency 3D (%) - Rare (26),Calcium Handling Analysis Method - Seahorse (35),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),3D Platform - Scaffold Free (43),Wnt Inhibitor - DS-I-7 (9),3D Stromal Cell Source - Cardiac Fibroblast (32),hiPSC-CM Media Supplement - bFGF (3),Deduced Culture Strategy - 2D Only (183),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),3D Tissue Media - RPMI-1640 (72),Day of Insulin Addition - not 25 (3),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Journal - Lab Chip (4),Insulin Start Day - 6 (20),Metabolic Component - IGF-1 (3),Maturation Strategy - Tension (64),Metabolic Component Category - Kinase Inhibitors (3),Seeding Confluency 2D (%) - 85 to 89 (26),Journal - PLoS One (9),Calcium Handling Analysis Method - Genetical (23),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),Seeding Confluency 3D (%) - 80 to 84 (5),Seeding Confluency 2D (%) - 70 to 79 (6),Metabolic Component - IGF-1 (3),Day of Insulin Addition - not 16 (15),Calcium Handling Analysis Method - Visual (104),hiPSC-CM Purification Duration (days) - 8 days (4),Insulin Start Day - After 11 (7),Publication Year - 2020 (51),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),hiPSC-CM Maturation Media - F12 (10),Publication Year - 2015 (19),Cell Line - BJ RiPS (4),3D Platform - Scaffold Free (43),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Insulin Start Day - 9 (10),Wnt Inhibitor - XAV939 (24),hiPSC Backbone Media - Rare (19),Journal - Tissue Eng Part A (4),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Journal - Rare (104),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Journal - Nat Biomed Eng (5),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Journal - Sci Rep (24),Number of Cell Lines - >5 (9),Cell Line - iCell2 (8),Publication Year - 2017 (43),Coating for Replating - Matrigel (65),Seeding Confluency 3D (%) - 90 to 94 (13),Journal - Int J Mol Sci (3),Gene Analysis Method - RNA (169),Publication Year - Late-2010s (196),Journal - Tissue Eng Part C Methods (6),Publication Year - 2021 (43),Maturation Strategy - ECM (21),Electrophysiology Analysis Method - Optical Mapping (39),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),hiPSC-CM Maturation Media - iCell Maintenance (83),3D Tissue Media - Rare (13),Publication Year - 2017 (43),Publication Year - 2020 (51),2D Surface - ECM-coated (115),Electrophysiology Analysis Method - Patch Clamp (59),Number of Cell Lines - >5 (9),Calcium Handling Analysis Method - Visual (104),Insulin Start Day - 3 (5),Wnt Inhibitor - IWP (112),Seeding Confluency 2D (%) - 95 to 100 (6),Maturation Strategy - Electrical (39),Number of Cell Lines - 4 (11),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)
3D Platform - Collagen (38),Cell Line - Rare (132),3D Platform - Matrigel (33),Publication Year - 2021 (43),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Journal - Circ Res (5),3D Tissue Media - Rare (13),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Insulin Start Day - 0 (7),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Electrophysiology Analysis Method - Patch Clamp (59),Coating for Replating - Synthemax (3),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Contractile Analysis Method - Force Transducer (27),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),,hiPSC Backbone Media - mTeSR (106),,3D Tissue Media - MEM-α (60),3D Platform - Scaffold Free (43),Maturation Strategy - ECM (21),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),hiPSC-CM Maturation Media - RPMI-1640 (153),Cell Line - IMR90 (19),Seeding Confluency 2D (%) - 90 to 94 (12),Contractile Analysis Method - Traction Force Microscopy (9),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Cell Line - IMR90 (19),Purification Protocol - Metabolic (8),Metabolic Component - Fatty Acid (13),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),hiPSC-CM Media Supplement - Rare (5),Journal - PLoS One (9),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Pharmacological Intervention - Carbenoxolone (4),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Publication Year - 2014 (3),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Calcium Handling Analysis Method - Rare (4),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Platform - Matrigel (33),,3D Endothelial Cell Source - hiPSC-EndothelialC (16),Journal - Nat Biomed Eng (5),3D Tissue Media - Growth Factor (12),Seeding Confluency (%) - 85 to 89 (43),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Coating for Replating - Matrigel (65),3D Stromal Cell Source - Rare (4),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),Insulin Start Day - 5 (14),Day of Insulin Addition - not 23 (10),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Contractile Analysis Method - Traction Force Microscopy (9),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Cell Line - ATCC (5),Pharmacological Intervention - QT-Prolonging Drugs (36),Wnt Induction - CHIR99021 (184),New Media for Maturation - Commercial Kit (5),Seeding Confluency (%) - 85 to 89 (43),Metabolic Component Category - Fatty Acids and Lipids (21),Maturation Strategy - ECM (21),hiPSC-CM Media Supplement - Lipid Mix (5),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Cell Line - C25 (6),Cell Line - BJ1 (7),Cell Line - 201B6 (3),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),Pharmacological Intervention - Cardiotoxic Agents (3),Coating for Replating - Gelatin (43),Pharmacological Intervention - QT-Prolonging Drugs (36),Metabolic Component - KOSR (3),Maturation Strategy - Mechanical (36),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),3D Platform - 3D printed (9),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),New Media for Maturation - Rare (4),Publication Year - 2017 (43),Journal - Sci Rep (24),Coating for Replating - Matrigel (65),Cell Line - WTC11 (30),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),2D Surface - Microelectrode Array (9),Electrophysiology Analysis Method - Optical Mapping (39),hiPSC-CM Purification Duration (days) - 8 days (4),hiPSC Backbone Media - iCell Maintenance (86),3D Tissue Media - Commercial Kit (21),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),Maturation Strategy - Electrical (39),Publication Year - 2020 (51),Coating for Replating - Gelatin (43),hiPSC-CM Maturation Media - Cor.4U Complete (6),Wnt Inhibitor Duration (days) - 3 days (17),3D Platform - Matrigel (33),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Maturation Strategy - ECM (21),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),hiPSC-CM Purification Duration (days) - 3 days (13),hiPSC Backbone Media - Essential 8 (82),Seeding Confluency (%) - 95 to 100 (23),Seeding Confluency 3D (%) - 85 to 89 (12),Maturation Strategy - Metabolic (33),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31)
Journal - Biosens Bioelectron (4),Wnt Inhibitor - IWP (112),Disease Modelling - Genetic Disorders (18),hiPSC Backbone Media - StemFlex (5),Journal - ACS Biomater Sci Eng (3),Gene Analysis Method - Rare (5),hiPSC Backbone Media - Rare (19),hiPSC-CM Media Supplement - Mercaptoethanol (10),Cell Line Ancestry - Caucasian (41),Cell Line - iCell2 (8),3D Endothelial Cell Source - hiPSC-EndothelialC (16),Coating for Replating - Rare (6),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Cell Line - BJ1 (7),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),,Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),,3D Endothelial Cell Source - Rare (3),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Maturation Strategy - Other Cells (80),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Journal - Rare (104),Pharmacological Intervention - Phenylephrine (3),Pharmacological Intervention - Positive Inotropes (9),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Journal - Cell Stem Cell (6),Journal - Am J Physiol Heart Circ Physiol (4),Seeding Confluency 3D (%) - 90 to 94 (13),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Insulin Start Day - 10 (6),Disease Modelling - Arrhythmic (15),Metabolic Component Category - Signaling Pathway Regulators (6),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Publication Year - 2017 (43),Maturation Strategy - Mechanical (36),,Seeding Confluency 3D (%) - Rare (26),Gene Analysis Method - RNA (169),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),,Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),hiPSC-CM Purification Duration (days) - <3 days (31),Wnt Induction Duration (days) - 3 days (38),hiPSC-CM Maturation Media - Commercial Kit (27),Journal - ACS Appl Mater Interfaces (4),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Cell Line Sex - Female (40),Cell Line - BJ RiPS (4),Insulin Withdrawal Duration (days) - 4 days (18),Deduced Culture Strategy - 3D Only (157),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Journal - Cell Stem Cell (6),Gene Analysis Method - RNA (169),Cell Line - Gibco episomal (10),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Disease Modelling - Hypertrophic Cardiomyopathy (6),Journal - Tissue Eng Part A (4),Day of Insulin Addition - Known (177),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),3D Tissue Media - Iscove (5),Publication Year - 2020 (51),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),hiPSC-CM Maturation Media - Cor.4U Complete (6),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Insulin Start Day - 4 (11),2D Surface - Electrospun (13),hiPSC-CM Media Supplement - Rare (5),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Disease Modelling - Genetic Disorders (18),3D Tissue Media - RPMI-1640 (72),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Pharmacological Intervention - Carbamylcholine (6),Seeding Confluency 3D (%) - Rare (26),Journal - Nat Biomed Eng (5),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),hiPSC Backbone Media - DMEM (10),Coating for Replating - Matrigel (65),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Journal - Sci Rep (24),Journal - Sci Rep (24),hiPSC-CM Purification Duration (days) - <3 days (31),Journal - Biomaterials (16),Publication Year - 2017 (43),Cell Line - Cor.4U (16),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Seeding Confluency 3D (%) - 85 to 89 (12),2D Surface - ECM-coated (115),Insulin Withdrawal Duration (days) - 8 days (3),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Coating for Replating - Rare (6),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Seeding Confluency 2D (%) - 80 to 84 (5),Cell Line Ancestry - Caucasian (41),Wnt Inhibitor - DS-I-7 (9),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Electrophysiology Analysis Method - Microelectrode (31),Cell Line Ancestry - Caucasian (41),Publication Year - 2018 (45),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),Day of Insulin Addition - not 10 (4),Cell Line - Cor.4U (16),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),3D Tissue Media - Commercial Kit (21)
Wnt Inhibitor - IWP (112),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Journal - J Mol Cell Card (6),Day of Insulin Addition - not 24 (9),Journal - Acta Biomater (10),Electrophysiology Analysis Method - Genetical (3),Pharmacological Intervention - QT-Prolonging Drugs (36),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Electron Imaging - Transmission (62),Insulin Start Day - 3 (5),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Journal - Stem Cell Res (8),hiPSC Backbone Media - Commercial CM Kit (12),Journal - Cell Stem Cell (6),Metabolic Component Category - Kinase Inhibitors (3),,Publication Year - 2019 (57),,3D Stromal Cell Source - hiPSC-SmoothMC (3),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Cell Coculture - Stromal Cell (78),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),hiPSC Backbone Media - Cor.4U Complete (6),Number of Cell Lines - 4 (11),Disease Modelling - Specialised (3),New Media for Maturation - RPMI-1640 (30),Coating for Replating - Geltrex (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Seeding Confluency (%) - 90 to 94 (26),Seeding Confluency 3D (%) - 80 to 84 (5),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),3D Tissue Media - Commercial Kit (21),Day of Insulin Addition - Known (177),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Journal - Stem Cells (11),,Gene Analysis Method - RNA (169),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),hiPSC Backbone Media - Conditioned (12),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),,3D Stromal Cell Source - hiPSC-CardiacF (8),3D Tissue Media - iCell Maintenance (12),hiPSC-CM Media Supplement - Ascorbic Acid (41),2D Surface - Decellularized ECM (3),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Seeding Confluency 2D (%) - 80 to 84 (5),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),hiPSC Matrix Coating - EBs (18),Insulin Withdrawal Duration (days) - 3 days (6),Cell Coculture - Cardiomyocyte (157),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),3D Platform - 3D printed (9),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Seeding Confluency (%) - 80 to 84 (12),Wnt Inhibitor - IWR (56),Insulin Withdrawal Duration (days) - 4 days (18),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Wnt Induction Duration (days) - 3 days (38),Differentiation Purity Assessment - Rare (3),hiPSC-CM Media Supplement - Lipids (9),Journal - Stem Cell Res (8),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Seeding Confluency 3D (%) - 80 to 84 (5),hiPSC-CM Media Supplement - Polyvinylalchohol (6),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),Coating for Replating - Synthemax (3),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Seeding Confluency 3D (%) - 95 to 100 (13),Seeding Confluency 2D (%) - Rare (13),Insulin Withdrawal Duration (days) - 4 days (18),Cell Line - SCVI-273 (8),hiPSC-CM Media Supplement - L-glutamine (19),Day of Insulin Addition - not 24 (9),Maturation Strategy - Electrical (39),Journal - Circulation (11),Seeding Confluency 3D (%) - 85 to 89 (12),hiPSC-CM Purification Duration (days) - <3 days (31),Wnt Inhibitor Duration (days) - Rare (173),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Journal - Tissue Eng Part C Methods (6),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Disease Modelling - Arrhythmic (15),hiPSC-CM Maturation Media - Rare (9),hiPSC Backbone Media - Rare (10),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),New Media for Maturation - Rare (4),3D Platform - Extracellular Scaffold (18),Publication Year - Post 2020 (122),hiPSC-CM Purification Duration (days) - >9 days (5),hiPSC-CM Purification Duration (days) - >9 days (5),hiPSC-CM Purification Duration (days) - 5 days (6),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),3D Platform - Extracellular Scaffold (18),3D Platform - Extracellular Scaffold (18),Coating for Replating - Geltrex (10),Calcium Handling Analysis Method - Visual (104),Number of Cell Lines - 3 (29),hiPSC-CM Maturation Media - iCell Maintenance (83),Electrophysiology Analysis Method - Microelectrode (31),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Coating for Replating - Gelatin (43),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),hiPSC Matrix Coating - Geltrex (33),hiPSC Backbone Media - iCell Maintenance (86),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),hiPSC-CM Media Supplement - Rare (5),Wnt Inhibitor Duration (days) - >6 days (12),Electrophysiology Analysis Method - Optical Mapping (39),Metabolic Component - Fatty Acid (13),Journal - Stem Cells (11),hiPSC Matrix Coating - Vitronectin (10),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Cell Coculture - Stromal Cell (78),Coating for Replating - Laminin (5),Metabolic Component Category - Kinase Inhibitors (3),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),hiPSC-CM Media Supplement - Lipids (9),Cell Line Sex - Both (118),Cell Line - 201B6 (3),,Day of Insulin Addition - not 22 (12),,Journal - Front Cell Dev Biol (3),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),3D Platform - Polyethylene Glycol (8),Wnt Induction - Wnt3a (3),Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Insulin Start Day - 2 (4),Seeding Confluency (%) - 90 to 94 (26),Day of Insulin Addition - not 14 (15),2D Surface - Electrospun (13),Wnt Induction - StemCell Diff Kit (4),Pharmacological Intervention - Cardiotoxic Agents (3),Wnt Inhibitor Duration (days) - 5 days (6),2D Surface - Hydrogel (17),Sacromere or Cellular Alignment Analysis - Yes (72),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Number of Cell Lines - >5 (9),Electrophysiology Analysis Method - Microelectrode (31),Seeding Confluency (%) - 70 to 79 (11),,Differentiation Purity Assessment - Rare (3),2D Surface - Micropatterned (27),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),,hiPSC Matrix Coating - Rare (8),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Journal - Cell Stem Cell (6),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Wnt Inhibitor - XAV939 (24),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),Day of Insulin Addition - not 24 (9),Electron Imaging - Scanning (22),Journal - Sci Adv (3),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Platform - Extracellular Scaffold (18),Differentiation Purity Assessment - IHC a-actinin (8),Wnt Induction Duration (days) Quantiles - Q2 (>1 and ≤2) (75),Seeding Confluency 3D (%) - Rare (26),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Day of Insulin Addition - not 12 (11),Journal - Nano Lett (3),3D Platform - Gelatin (6),Publication Year - 2018 (45),Cell Line - iCell2 (8),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Journal - Rare (104),2D Surface - Nanotopography (6),Seeding Confluency 2D (%) - 90 to 94 (12),3D Tissue Media - Growth Factor (12),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),hiPSC-CM Media Supplement - GlutaMax (8),hiPSC-CM Media Supplement - Lipids (9),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Coating for Replating - Fibronectin (32),Metabolic Component - Fatty Acid (13),Contractile Analysis Method - Traction Force Microscopy (9),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),Maturation Strategy - Other Cells (80),Contractile Analysis Method - Deflection (39),Seeding Confluency (%) - 95 to 100 (23),Cell Line - iCell (47),3D Platform - Nanotechnology (3),Coating for Replating - Gelatin (43),Number of Cell Lines - 3 (29),Journal - Nat Commun (13),Cell Line - Cor.4U (16),3D Tissue Media - MEM-α (60),Number of Cell Lines - 4 (11),Journal - Biomaterials (16),Coating for Replating - Gelatin (43),Cell Line - 253G1 (10),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Maturation Strategy - ECM (21),3D Tissue Media - Rare (13),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),Contractile Analysis Method - Traction Force Microscopy (9),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Contractile Analysis Method - Traction Force Microscopy (9),Journal - Sci Rep (24),Electrophysiology Analysis Method - Microelectrode (31),Insulin Start Day - 4 (11),2D Surface - Nanotopography (6),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Insulin Start Day - 9 (10),Publication Year - Post 2020 (122),Journal - Circ Res (5),3D Tissue Media - Iscove (5)
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Disease Modelling - Hypertrophic Cardiomyopathy (6),Pharmacological Intervention - T3 (3),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Fatty Acid Metabolism Assessed - Yes (20),Pharmacological Intervention - Other Antiarrhythmic Agents (13),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Coating for Replating - Rare (6),hiPSC Backbone Media - Commercial CM Kit (12),New Media for Maturation - Commercial Kit (5),3D Endothelial Cell Source - hiPSC-EndothelialC (16),,,Cell Line - 201B6 (3),,Cell Line - 201B6 (3),3D Stromal Cell Source - Dermal Fibroblast (7),3D Tissue Media - RPMI-1640 (72),Maturation Strategy - Electrical (39),Differentiation Purity Assessment - IHC cTnT (7),Disease Modelling - Dilated Cardiomyopathy (6),2D Surface - ECM-coated (115),hiPSC-CM Purification Duration (days) - >9 days (5),Seeding Confluency 2D (%) - 85 to 89 (26),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),3D Stromal Cell Source - hiPSC-CardiacF (8),Pharmacological Intervention - Carbenoxolone (4),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Cell Coculture - Cardiomyocyte (157),hiPSC Matrix Coating - Vitronectin (10),Journal - ACS Appl Mater Interfaces (4),Journal - ACS Biomater Sci Eng (3),,,Publication Year - 2014 (3),3D Stromal Cell Source - Mesenchymal Stem Cell (12),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),,3D Stromal Cell Source - Human Fibroblast (38),hiPSC-CM Media Supplement - VEGF (4),2D Surface - Microparticle/fluid (3),Journal - Circulation (11),Wnt Inhibitor Duration (days) - Rare (173),Journal - Stem Cells Int (3),3D Platform - Polyethylene Glycol (8),3D Platform - Collagen (38),Journal - PNAS (3),Publication Year - 2020 (51),3D Stromal Cell Source - Stromal Cell (35),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),3D Platform - Polyethylene Glycol (8),Maturation Strategy - Cell Alignment (59),3D Tissue Media - iCell Maintenance (12),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Seeding Confluency 2D (%) - 85 to 89 (26),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),3D Platform - Nanotechnology (3),Wnt Inhibitor - IWR (56),Journal - Cell Stem Cell (6),Insulin Withdrawal Duration (days) - 8 days (3),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Coating for Replating - Laminin (5),Calcium Handling Analysis Method - Rare (4),Cell Line - iCell2 (8),Seeding Confluency 2D (%) - 95 to 100 (6),hiPSC-CM Maturation Media - iCell Maintenance (83),3D Stromal Cell Source - Rare (4),hiPSC-CM Media Supplement - Mercaptoethanol (10),hiPSC-CM Purification Duration (days) - 4 days (29),Journal - J Mol Cell Card (6),hiPSC-CM Media Supplement - Polyvinylalchohol (6),Day of Insulin Addition - not 23 (10),hiPSC Backbone Media - Rare (10),Number of Cell Lines - 2 (50),Metabolic Component - Ascorbic Acid (3),Deduced Culture Strategy - 2D Only (183),Cell Line Sex - Male (64),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Tissue Media - Growth Factor (12),hiPSC-CM Purification Duration (days) - 5 days (6),3D Tissue Media - Growth Factor (12),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Cell Line Ancestry - Caucasian (41),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Coating for Replating - Gelatin (43),hiPSC-CM Media Supplement - GlutaMax (8),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),3D Platform - Polyethylene Glycol (8),Wnt Inhibitor - VEGF (3),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Insulin Start Day - 6 (20),hiPSC-CM Purification Duration (days) - 5 days (6),Calcium Handling Analysis Method - Visual (104),Coating for Replating - Rare (6),Disease Modelling - Hypertrophic Cardiomyopathy (6),Cell Line - Cor.4U (16),Disease Modelling - Dilated Cardiomyopathy (6),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),3D Stromal Cell Source - hiPSC-CardiacF (8),Coating for Replating - Rare (6),2D Surface - Microelectrode Array (9),hiPSC-CM Purification Duration (days) - <3 days (31),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Publication Year - 2015 (19),3D Platform - Extracellular Scaffold (18),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),hiPSC Backbone Media - iCell Maintenance (86)
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Metabolic Component - Insulin-Transferrin-Selenium (3),Publication Year - 2014 (3),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Cell Line - BJ RiPS (4),hiPSC-CM Purification Duration (days) - >9 days (5),3D Platform - Extracellular Scaffold (18),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),hiPSC Backbone Media - iCell Maintenance (86),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Maturation Strategy - Electrical (39),Publication Year - 2018 (45),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),,,,,,,Maturation Strategy - Mechanical (36),Maturation Strategy - ECM (21),Coating for Replating - Matrigel (65),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),Wnt Inhibitor - Wnt-C59 (30),hiPSC Backbone Media - Essential 8 (82),Metabolic Component - Rare (4),Journal - J Mol Cell Card (6),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),,Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Cell Line - iCell2 (8),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),,,Day of Insulin Addition - not 25 (3),3D Platform - 3D printed (9),3D Tissue Media - Commercial Kit (21),,3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),hiPSC-CM Maturation Media - Commercial Kit (27),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),3D Stromal Cell Source - Rare (4),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),hiPSC-CM Maturation Media - Commercial Kit (27),Gene Analysis Method - Rare (5),Maturation Strategy - Other Cells (80),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Maturation Strategy - Elastomeric (33),Cell Line - SCVI-273 (8),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Journal - J Mol Cell Card (6),Metabolic Component Category - Hormonal Stimulation (14),Cell Line - PGP1 (11),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Calcium Handling Analysis Method - Flux Rates (13),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Publication Year - 2015 (19),Journal - Stem Cell Res Ther (3),3D Tissue Media - Rare (13),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Cell Line - BJ1 (7),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),hiPSC Backbone Media - DMEM (10),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Contractile Analysis Method - Motion Tracking (93),Journal - Circulation (11),2D Surface - ECM-coated (115),Publication Year - 2022 (20),Cell Line - PGP1 (11),Cell Line - iCell2 (8),Cell Line - BJ1 (7),Journal - Toxicological Sciences (4),New Media for Maturation - Rare (4),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Cell Line - Cor.4U (16),Disease Modelling - Hypertrophic Cardiomyopathy (6),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Number of Cell Lines - >5 (9),hiPSC-CM Media Supplement - Transferrin (11),Disease Modelling - Arrhythmic (15),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Publication Year - 2016 (32),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),hiPSC-CM Media Supplement - Lipid Mix (5),Contractile Analysis Method - Motion Tracking (93),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Number of Cell Lines - 4 (11),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),2D Surface - Microelectrode Array (9),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),Number of Cell Lines - 4 (11),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Publication Year - 2019 (57),3D Tissue Media - Rare (13),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Publication Year - 2020 (51),Contractile Analysis Method - Motion Tracking (93),Publication Year - 2018 (45),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Sacromere or Cellular Alignment Analysis - Yes (72)
Pharmacological Intervention - Caffeine (4),2D Surface - Microparticle/fluid (3),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),2D Surface - Hydrogel (17),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Disease Modelling - Dilated Cardiomyopathy (6),Publication Year - 2024 (7),Sacromere or Cellular Alignment Analysis - Yes (72),3D Tissue Media - Iscove (5),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),,Seeding Confluency 2D (%) - 95 to 100 (6),,Seeding Confluency (%) - 85 to 89 (43),,,,,,,Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Platform - Extracellular Scaffold (18),Journal - Stem Cell Res (8),hiPSC-CM Media Supplement - HEPES (16),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),3D Stromal Cell Source - Cardiac Fibroblast (32),hiPSC-CM Purification Duration (days) - 6 days (10),Publication Year - 2014 (3),Insulin Start Day - 9 (10),hiPSC-CM Purification Duration (days) - >9 days (5),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Journal - Sci Transl Med (3),,Metabolic Component Category - Sugars and Carbohydrates (9),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Disease Modelling - Genetic Disorders (18),,,,3D Stromal Cell Source - Dermal Fibroblast (7),Seeding Confluency 3D (%) - 85 to 89 (12),,hiPSC Backbone Media - StemFit (5),Calcium Handling Analysis Method - Flux Rates (13),Journal - ACS Appl Mater Interfaces (4),2D Surface - ECM-coated (115),Day of Insulin Addition - Known (177),Cell Line - DF19-9-11T.H (16),hiPSC-CM Media Supplement - Mercaptoethanol (10),Insulin Start Day - After 11 (7),Journal - Cell Stem Cell (6),Journal - Nat Biomed Eng (5),Insulin Withdrawal Duration (days) - 4 days (18),Pharmacological Intervention - Thalidomide (3),Cell Coculture - Cardiomyocyte (157),Insulin Start Day - 9 (10),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Wnt Inhibitor - BMP4 (7),3D Tissue Media - High-glucose DMEM (9),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Calcium Handling Analysis Method - Genetical (23),Publication Year - 2020 (51),Insulin Start Day - 8 (15),Insulin Start Day - 11 (3),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Disease Modelling - Specialised (3),Calcium Handling Analysis Method - Visual (104),Journal - Stem Cells (11),Purification Protocol - Metabolic (8),Insulin Start Day - 4 (11),Journal - PLoS One (9),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Wnt Induction Duration (days) - 4 days (15),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Maturation Strategy - ECM (21),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),3D Stromal Cell Source - Stromal Cell (35),Cell Line - BJ1 (7),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Cell Line - iCell2 (8),3D Platform - Gelatin (6),Electron Imaging - Scanning (22),Journal - Int J Mol Sci (3),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Journal - Sci Rep (24),Journal - Rare (104),Wnt Inhibitor - KY02111 (7),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),2D Surface - ECM-coated (115),Maturation Strategy - Other Cells (80),Coating for Replating - Gelatin (43),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),2D Surface - Microelectrode Array (9),2D Surface - ECM-coated (115),2D Surface - Microelectrode Array (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Platform - Collagen (38),Number of Cell Lines - >5 (9),Number of Cell Lines - 4 (11),Maturation Strategy - ECM (21),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Publication Year - 2021 (43),Coating for Replating - Synthemax (3),hiPSC-CM Media Supplement - B27 (180),hiPSC Backbone Media - Rare (19),Publication Year - Post 2020 (122)
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),hiPSC-CM Media Supplement - GlutaMax (8),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Seeding Confluency (%) - 95 to 100 (23),Journal - Biomater Sci (7),Metabolic Component - Palmitic Acid (11),Insulin Start Day - 7 (85),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),Pharmacological Intervention - Statins (Lipid-Lowering Agents) (3),Pharmacological Intervention - Propranolol (5),,Insulin Start Day - 4 (11),,Metabolic Component - IGF-1 (3),,,,,,,3D Stromal Cell Source - hiPSC-CardiacF (8),Wnt Inhibitor - Others (9),2D Surface - Electrospun (13),Wnt Inhibitor Duration (days) - 5 days (6),hiPSC-CM Purification Duration (days) - 6 days (10),Insulin Start Day - 1 (19),Calcium Handling Analysis Method - Rare (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Journal - J Biomed Mater Res A (3),hiPSC-CM Maturation Media - RPMI-1640 (153),Calcium Handling Analysis Method - Genetical (23),Insulin Start Day - 11 (3),,Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Wnt Inhibitor - KY02111 (7),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),,,,,3D Tissue Media - Iscove (5),,3D Platform - 3D printed (9),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Publication Year - 2014 (3),Publication Year - 2016 (32),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Journal - Stem Cells (11),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Journal - Circulation (11),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),Day of Insulin Addition - not 22 (12),Contractile Analysis Method - Rare (7),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Pharmacological Intervention - Epinephrine (11),Journal - Nat Biomed Eng (5),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),Journal - Stem Cell Reports (23),Calcium Handling Analysis Method - Genetical (23),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),hiPSC-CM Maturation Media - iCell Maintenance (83),3D Tissue Media - DMEM (53),Metabolic Component - Dexamethasone (7),3D Stromal Cell Source - hiPSC-SmoothMC (3),Wnt Inhibitor - KY02111 (7),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Cell Line - iCell (47),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Seeding Confluency 3D (%) - 85 to 89 (12),Publication Year - 2022 (20),hiPSC-CM Media Supplement - Selenium (7),3D Stromal Cell Source - hiPSC-MuralC (3),,Journal - Biosens Bioelectron (4),Pharmacological Intervention - Lidocaine (7),hiPSC-CM Purification Duration (days) - 7 days (6),Pharmacological Intervention - Positive Inotropes (9),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),New Media for Maturation - Rare (4),Journal - Lab Chip (4),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Seeding Confluency (%) - 80 to 84 (12),Wnt Inhibitor - KY02111 (7),Cell Line Ancestry - Asian (28),Cell Line Ancestry - Asian (28),Cell Line Ancestry - Asian (28),3D Platform - Extracellular Scaffold (18),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Coating for Replating - Gelatin (43),3D Endothelial Cell Source - Rare (3),3D Endothelial Cell Source - Rare (3),Journal - Cell Rep (6),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),2D Surface - Microelectrode Array (9),Publication Year - 2017 (43),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),,Journal - Nat Biomed Eng (5),Publication Year - 2019 (57),3D Platform - Extracellular Scaffold (18),Number of Cell Lines - >5 (9),New Media for Maturation - Rare (4),hiPSC-CM Media Supplement - Albumin (28),Differentiation Purity Assessment - IHC a-actinin (8),Insulin Start Day - 8 (15),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Maturation Strategy - ECM (21),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Publication Year - 2019 (57)
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Contractile Analysis Method - Rare (7),hiPSC Backbone Media - DMEM (10),Pharmacological Intervention - Verapamil (27),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Electrophysiology Analysis Method - Patch Clamp (59),Pharmacological Intervention - Carbamylcholine (6),Journal - J Mol Cell Cardiol (4),,Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),,hiPSC Backbone Media - Conditioned (12),,Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),,,,,,,Pharmacological Intervention - Carbenoxolone (4),hiPSC-CM Purification Duration (days) - 6 days (10),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),New Media for Maturation - F12 (7),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Insulin Start Day - 6 (20),Journal - Circulation (11),Journal - Biomater Sci (7),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Cell Line - IMR90 (19),Disease Modelling - Specialised (3),,Maturation Strategy - Electrical (39),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Electrophysiology Analysis Method - Optical Mapping (39),,,,,,,Journal - Sci Rep (24),3D Platform - 3D printed (9),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Wnt Inhibitor Duration (days) - 3 days (17),Publication Year - 2017 (43),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),hiPSC-CM Media Supplement - Ascorbic Acid (41),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Contractile Analysis Method - Traction Force Microscopy (9),Seeding Confluency 2D (%) - 90 to 94 (12),Seeding Confluency 2D (%) - Rare (13),Calcium Handling Analysis Method - Genetical (3),Wnt Inhibitor - BMP4 (7),Pharmacological Intervention - Cisapride (8),Cell Line - BJ RiPS (4),Insulin Withdrawal Duration (days) - 8 days (3),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Metabolic Component Category - Kinase Inhibitors (3),hiPSC Backbone Media - Embryonic Stem Cell (127),hiPSC-CM Purification Duration (days) - <3 days (31),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),Number of Cell Lines - 4 (11),Pharmacological Intervention - QT-Prolonging Drugs (36),Publication Year - 2018 (45),hiPSC-CM Media Supplement - Polyvinylalchohol (6),Pharmacological Intervention - QT-Prolonging Drugs (36),3D Platform - Matrigel (33),Metabolic Component Category - Kinase Inhibitors (3),3D Stromal Cell Source - hiPSC-MuralC (3),Calcium Handling Analysis Method - Genetical (23),Metabolic Component - Ascorbic Acid (3),Cell Line - 201B6 (3),,Insulin Start Day - 2 (4),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),New Media for Maturation - Commercial Kit (5),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),2D Surface - Micropatterned (27),3D Tissue Media - iCell Maintenance (12),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Journal - Toxicological Sciences (4),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),hiPSC-CM Media Supplement - Lipid Mix (5),Sacromere or Cellular Alignment Analysis - Yes (72),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),Coating for Replating - Fibronectin (32),Journal - Cell Rep (6),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),hiPSC-CM Purification Duration (days) Quantiles - Q1 (>4 and ≤20) (31),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Wnt Inhibitor - KY02111 (7),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),hiPSC-CM Purification Duration (days) - 5 days (6),Disease Modelling - Genetic Disorders (18),,Number of Cell Lines - >5 (9),,Coating for Replating - Rare (6),Journal - Nano Lett (3),,Disease Modelling - Arrhythmic (15),Seeding Confluency 2D (%) - 95 to 100 (6),Gene Analysis Method - RNA (169),Maturation Strategy - ECM (21),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),New Media for Maturation - F12 (7),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)
Journal - Nat Commun (13),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Pharmacological Intervention - Isoproterenol (71),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Insulin Start Day - 1 (19),Disease Modelling - Dilated Cardiomyopathy (6),2D Surface - Electrospun (13),,Cell Line - iCell (47),,,,Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),,,,,,,Electron Imaging - Scanning (22),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Journal - Stem Cell Res Ther (3),Day of Insulin Addition - not 25 (3),hiPSC-CM Maturation Media - RPMI-1640 (153),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Day of Insulin Addition - not 22 (12),Wnt Inhibitor - XAV939 (24),Pharmacological Intervention - Blebbistatin (5),,,,,New Media for Maturation - Rare (4),,Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),,,,,,,Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Metabolic Component Category - Sugars and Carbohydrates (9),Pharmacological Intervention - Propranolol (5),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),hiPSC-CM Media Supplement - Lipids (9),3D Platform - Gelatin (6),Metabolic Component Category - Hormonal Stimulation (14),Journal - Sci Transl Med (3),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),,Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Maturation Strategy - Metabolic (33),Seeding Confluency 2D (%) - 95 to 100 (6),Seeding Confluency 2D (%) - 90 to 94 (12),Pharmacological Intervention - Rare (3),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),hiPSC-CM Purification Duration (days) - 5 days (6),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),,Calcium Handling Analysis Method - Genetical (3),Metabolic Component - IGF-1 (3),,Pharmacological Intervention - E4031 (22),,Pharmacological Intervention - Carbamylcholine (6),Metabolic Component - Dexamethasone (7),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Seeding Confluency 3D (%) - 85 to 89 (12),Metabolic Component - KOSR (3),3D Endothelial Cell Source - hiPSC-EndothelialC (16),,Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Insulin Start Day - 3 (5),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),Contractile Analysis Method - Motion Tracking (93),Publication Year - 2017 (43),3D Platform - Gelatin (6),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Gene Analysis Method - Rare (5),3D Tissue Media - Rare (13),hiPSC Backbone Media - Rare (10),Electrophysiology Analysis Method - Optical Mapping (39),Cell Line - iCell2 (8),Cell Line - Cellapy (4),Wnt Induction - bFGF (45),Wnt Inhibitor - BMP4 (7),Maturation Strategy - Mechanical (36),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Journal - Cell Stem Cell (6),Wnt Inhibitor - BMP4 (7),Wnt Inhibitor - BMP4 (7),hiPSC-CM Maturation Media - Cor.4U Complete (6),,,,,Differentiation Purity Assessment - IHC a-actinin (8),,Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Journal - Nano Lett (3),Electrophysiology Analysis Method - Patch Clamp (59),hiPSC-CM Media Supplement - bFGF (3),3D Tissue Media - iCell Maintenance (12)
Metabolic Component Category - Kinase Inhibitors (3),Wnt Inhibitor - XAV939 (24),Electrophysiology Analysis Method - Optical Mapping (39),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),,Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Insulin Start Day - 8 (15),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),,Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),,,,3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),,,,,,,3D Tissue Media - Rare (13),hiPSC Backbone Media - iCell Maintenance (86),Pharmacological Intervention - Verapamil (27),Journal - PLoS One (9),Maturation Strategy - ECM (21),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Differentiation Purity Assessment - IHC cTnT (7),hiPSC Backbone Media - Conditioned (12),Publication Year - 2015 (19),,,,,Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),,,,,,,,,Seeding Confluency 3D (%) - 85 to 89 (12),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),,3D Stromal Cell Source - Rare (4),Cell Line - DF19-9-11T.H (16),Publication Year - Late-2010s (196),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Contractile Analysis Method - Rare (7),hiPSC-CM Media Supplement - 1-thioglycerol (14),Contractile Analysis Method - Force Transducer (27),Cell Line - iCell2 (8),Pharmacological Intervention - Cardiotoxic Agents (3),,3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),2D Surface - Micropatterned (27),,,Electrophysiology Analysis Method - Optical Mapping (39),Fatty Acid Metabolism Assessed - Yes (20),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),hiPSC-CM Media Supplement - Ascorbic Acid (41),Journal - ACS Biomater Sci Eng (3),,Journal - Circulation (11),3D Platform - Matrigel (33),,Wnt Inhibitor - IWP (112),,Journal - Circ Res (5),hiPSC-CM Maturation Media - Rare (9),hiPSC-CM Media Supplement - Selenium (7),Day of Insulin Addition - not 13 (13),hiPSC Backbone Media - Conditioned (12),,,TNNI3 Precentage (TTNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Metabolic Component - Galactose (4),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),,Gene Analysis Method - Rare (5),Purification Protocol - Cell Sorting (7),Cell Line - Cellapy (4),hiPSC-CM Media Supplement - Selenium (7),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Journal - Nat Commun (13),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Journal - Cell Rep (6),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Insulin Start Day - 0 (7),Wnt Inhibitor - VEGF (3),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Publication Year - 2017 (43),Cell Line - iCell (47),Insulin Start Day - 11 (3),,,,,Electrophysiology Analysis Method - Genetical (3),,Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Publication Year - 2016 (32),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),,Seeding Confluency 3D (%) - 90 to 94 (13),Publication Year - Late-2010s (196),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)
hiPSC-CM Purification Duration (days) - 6 days (10),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Publication Year - 2015 (19),Cell Line - Cor.4U (16),,Coating for Replating - Gelatin (43),hiPSC Backbone Media - StemFit (5),Publication Year - 2018 (45),,Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),,,,Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),,,,,,,3D Platform - Nanotechnology (3),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),hiPSC Backbone Media - Conditioned (12),Insulin Start Day - 6 (20),3D Tissue Media - High-glucose DMEM (9),2D Surface - Microparticle/fluid (3),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),,,,,,Wnt Inhibitor Duration (days) - >6 days (12),,,,,,,,,hiPSC Backbone Media - Rare (10),Coating for Replating - Fibronectin (32),,Calcium Handling Analysis Method - Visual (104),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),,Seeding Confluency (%) - 90 to 94 (26),Day of Insulin Addition - not 21 (14),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),,Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Gene Analysis Method - RNA (169),,,Insulin Start Day - 2 (4),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Coating for Replating - Vitronectin (3),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),,Journal - Biomaterials (16),,,Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),,,Purification Protocol - Cell Sorting (7),Cell Line - 201B6 (3),Pharmacological Intervention - Thalidomide (3),Journal - Stem Cells Int (3),,,Pharmacological Intervention - Caffeine (4),hiPSC-CM Maturation Media - Cor.4U Complete (6),Gene Analysis Method - RNA (169),hiPSC-CM Maturation Media - RPMI-1640 (153),Insulin Start Day - 8 (15),,,Seeding Confluency 3D (%) - 80 to 84 (5),Purification Protocol - Cell Sorting (7),Wnt Inhibitor Duration (days) - 4 days (19),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),,Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),,Journal - Sci Transl Med (3),3D Tissue Media - Commercial Kit (21),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),,Publication Year - Post 2020 (122),Contractile Analysis Method - Motion Tracking (93),Electrophysiology Analysis Method - Genetical (3),,,,,Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),,,,3D Stromal Cell Source - Cardiac Fibroblast (32),,2D Surface - Decellularized ECM (3),Metabolic Component - Albumax (3),3D Platform - Fibronectin (3)
,Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),hiPSC-CM Purification Duration (days) - 5 days (6),3D Tissue Media - High-glucose DMEM (9),,Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),3D Platform - Nanotechnology (3),Pharmacological Intervention - Caffeine (4),,hiPSC Backbone Media - iCell Maintenance (86),,,,Seeding Confluency 3D (%) - 85 to 89 (12),,,,,,,Cell Line - iCell (47),hiPSC-CM Purification Duration (days) Quantiles - Q1 (>4 and ≤20) (31),Cell Line - Cellapy (4),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Publication Year - 2024 (7),Journal - Biomaterials (16),Sacromere or Cellular Alignment Analysis - Yes (72),Calcium Handling Analysis Method - Seahorse (35),,,,,,,,,,,,,,,Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Pharmacological Intervention - Verapamil (27),,Pharmacological Intervention - T3 (3),,Metabolic Component Category - Amino Acids and Derivatives (9),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Disease Modelling - Genetic Disorders (18),,Number of Cell Lines - 4 (11),Wnt Inhibitor - XAV939 (24),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),,Cell Coculture - Endothelial Cell (35),Wnt Inhibitor Duration (days) - 3 days (17),,,2D Surface - Hydrogel (17),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),2D Surface - ECM-coated (115),Publication Year - Post 2020 (122),,Wnt Inhibitor Duration (days) - 6 days (4),,,Metabolic Component - Dexamethasone (7),,,Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Pharmacological Intervention - Thalidomide (3),,,,,Coating for Replating - Geltrex (10),Journal - Cell Stem Cell (6),Wnt Induction Duration (days) - 3 days (38),,Wnt Inhibitor - Wnt-C59 (30),,,Gene Analysis Method - Rare (5),Maturation Strategy - ECM (21),Number of Cell Lines - 3 (29),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),,Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),hiPSC Backbone Media - Cor.4U Complete (6),Wnt Inhibitor - XAV939 (24),,3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Number of Cell Lines - >5 (9),,Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Publication Year - Late-2010s (196),,,,,,,,,,Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),,,Metabolic Component - Ascorbic Acid (3),
,hiPSC-CM Purification Duration (days) - 7 days (6),,Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),,Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),Seeding Confluency (%) - 95 to 100 (23),Wnt Inhibitor Duration (days) - 5 days (6),,,,,,Wnt Inhibitor - Rare (3),,,,,,,Journal - Biomater Sci (7),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),,3D Tissue Media - iCell Maintenance (12),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Electrophysiology Analysis Method - Genetical (3),Pharmacological Intervention - Metoprolol (5),Journal - ACS Biomater Sci Eng (3),,,,,,,,,,,,,,,Purification Protocol - Antibiotic (4),,,Day of Insulin Addition - not 22 (12),,Metabolic Component - Palmitic Acid (11),Journal - Am J Physiol Heart Circ Physiol (4),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),,Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Journal - J Mol Cell Card (6),,,3D Tissue Media - High-glucose DMEM (9),,,,Journal - Stem Cells (11),,TNNI3 Precentage (TTNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),,Sacromere or Cellular Alignment Analysis - Yes (72),,,Disease Modelling - Hypertrophic Cardiomyopathy (6),,,hiPSC-CM Media Supplement - VEGF (4),,,,,,Journal - Stem Cell Res Ther (3),hiPSC Backbone Media - Cor.4U Complete (6),,,hiPSC Backbone Media - mTeSR (106),,,,Journal - Tissue Eng Part C Methods (6),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Electrophysiology Analysis Method - Optical Mapping (39),,Electron Imaging - Scanning (22),Cell Line - iCell (47),hiPSC Backbone Media - Cor.4U Complete (6),,,Wnt Inhibitor - Wnt-C59 (30),,,Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),,,,,,,,,,,,,,Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),
,Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),,Pharmacological Intervention - T3 (3),,Seeding Confluency 2D (%) - 85 to 89 (26),Maturation Strategy - ECM (21),Journal - PLoS One (9),,,,,,New Media for Maturation - RPMI-1640 (30),,,,,,,Pharmacological Intervention - Cisapride (8),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),,Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Journal - Circ Res (5),Journal - Stem Cells Transl Med (3),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),,,,,,,,,,,,,,,Day of Insulin Addition - not 17 (12),,,Electron Imaging - Transmission (62),,hiPSC Backbone Media - StemPro-34 (14),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),,Disease Modelling - Fibrotic (4),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Coating for Replating - Matrigel (65),,,,,,,Journal - Cell Stem Cell (6),,Pharmacological Intervention - Carbamylcholine (6),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),,New Media for Maturation - F12 (7),,,Disease Modelling - Arrhythmic (15),,,Wnt Inhibitor - bFGF (8),,,,,,,Contractile Analysis Method - Rare (7),,,Contractile Analysis Method - Traction Force Microscopy (9),,,,hiPSC-CM Media Supplement - HEPES (16),Insulin Start Day - 11 (3),Number of Cell Lines - 3 (29),,Seeding Confluency 3D (%) - 70 to 79 (3),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),,,Insulin Start Day - 0 (7),,,Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),,,,,,,,,,,,,,,
,,,Journal - Circulation (11),,Insulin Withdrawal Duration (days) Quantiles - Q1 (>4 and ≤10) (11),,Coating for Replating - Matrigel (65),,,,,,,,,,,,,3D Tissue Media - High-glucose DMEM (9),Pharmacological Intervention - Phenylephrine (3),,Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),,Seeding Confluency (%) - 85 to 89 (43),Insulin Withdrawal Duration (days) - 6 days (3),Journal - Biomater Sci (7),,,,,,,,,,,,,,,3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),,,Coating for Replating - Rare (6),,Cell Line - PGP1 (11),Insulin Start Day - 8 (15),Insulin Start Day - 3 (5),,Insulin Start Day - 3 (5),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Coating for Replating - Fibronectin (32),,,,,,,,,,2D Surface - ECM-coated (115),,,,,,,,hiPSC Backbone Media - StemPro-34 (14),,,,,,,Seeding Confluency (%) - 80 to 84 (12),,,3D Platform - 3D printed (9),,,,Seeding Confluency 3D (%) - 80 to 84 (5),,3D Stromal Cell Source - hiPSC-CardiacF (8),,,Seeding Confluency 3D (%) - 80 to 84 (5),,,,Journal - Sci Transl Med (3),,,3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),,,,,,,,,,,,,,,
,,,Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),,,,Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),,,,,,,,,,,,,Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Cell Line - C25 (6),,Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),,Insulin Start Day - 3 (5),Cell Line Ancestry - Asian (28),,,,,,,,,,,,,,,,,,,,,,hiPSC-CM Media Supplement - B27 (180),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),,Journal - PLoS One (9),Seeding Confluency 3D (%) - 80 to 84 (5),,,,,,,,,,,,,,,,,,,hiPSC-CM Maturation Media - F12 (10),,,,,,,Journal - Sci Transl Med (3),,,Electron Imaging - Transmission (62),,,,Journal - Toxicological Sciences (4),,,,,hiPSC Backbone Media - DMEM (10),,,,3D Tissue Media - Rare (13),,,,,,,,,,,,,,,,,,
,,,hiPSC Backbone Media - Embryonic Stem Cell (127),,,,Calcium Handling Analysis Method - Rare (4),,,,,,,,,,,,,3D Tissue Media - Iscove (5),3D Stromal Cell Source - hiPSC-SmoothMC (3),,,,3D Platform - Gelatin (6),Journal - Biomater Sci (7),,,,,,,,,,,,,,,,,,,,,,Journal - PLoS One (9),,,Journal - ACS Biomater Sci Eng (3),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),,,,,,,,,,,,,,,,,,,3D Tissue Media - Rare (13),,,,,,,Journal - Biosens Bioelectron (4),,,Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),,,,3D Platform - Gelatin (6),,,,,2D Surface - Decellularized ECM (3),,,,3D Tissue Media - Growth Factor (12),,,,,,,,,,,,,,,,,,
,,,Differentiation Purity Assessment - Visual Inspection (6),,,,2D Surface - ECM-coated (115),,,,,,,,,,,,,hiPSC Matrix Coating - Matrigel (163),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),,,,hiPSC-CM Media Supplement - HEPES (16),Insulin Withdrawal Duration (days) - 8 days (3),,,,,,,,,,,,,,,,,,,,,,,,,Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),,,,,,,,,,,,,,,,,,,,,,,,,,,Wnt Induction - Rare (4),,,hiPSC Backbone Media - Embryonic Stem Cell (127),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,hiPSC-CM Purification Duration (days) - 7 days (6),,,,Seeding Confluency 2D (%) - 90 to 94 (12),,,,,,,,,,,,,Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Journal - J Tissue Eng (4),,,,3D Platform - Polyethylene Glycol (8),Calcium Handling Analysis Method - Flux Rates (13),,,,,,,,,,,,,,,,,,,,,,,,,Journal - J Mol Cell Cardiol (4),,,,,,,,,,,,,,,,,,,,,,,,,,,Maturation Strategy - Electrical (39),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,hiPSC-CM Purification Duration (days) Quantiles - Q1 (>4 and ≤20) (31),,,,,,,,,,,,,,,,,Disease Modelling - Fibrotic (4),hiPSC Backbone Media - Conditioned (12),,,,Seeding Confluency 3D (%) - 70 to 79 (3),,,,,,,,,,,,,,,,,,,,,,,,,,Insulin Start Day - 11 (3),,,,,,,,,,,,,,,,,,,,,,,,,,,Insulin Start Day - 9 (10),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,Journal - J Mol Cell Cardiol (4),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Contractile Analysis Method - Motion Tracking (93),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
